

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
07 October 2023 :: Issue 721
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



[The Nobel Prize in Physiology or Medicine 2023](#)

Press Release, 2023-10-02

The Nobel Assembly at Karolinska Institutet has today decided to award the 2023 Nobel Prize in Physiology or Medicine jointly to **Katalin Karikó and **Drew Weissman** for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19**

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19 during the pandemic that began in early 2020. Through their groundbreaking findings, which have fundamentally changed our understanding of how mRNA interacts with our immune system, the laureates contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times...

Katalin Karikó was born in 1955 in Szolnok, Hungary. She received her PhD from Szeged's University in 1982 and performed postdoctoral research at the Hungarian Academy of Sciences in Szeged until 1985. She then conducted postdoctoral research at Temple University, Philadelphia, and the University of Health Science, Bethesda. In 1989, she was appointed Assistant Professor at the University of Pennsylvania, where she remained until 2013. After that, she became vice president and later senior vice president at BioNTech RNA Pharmaceuticals. Since 2021, she has been a Professor at Szeged University and an Adjunct Professor at Perelman School of Medicine at the University of Pennsylvania.

Drew Weissman was born in 1959 in Lexington, Massachusetts, USA. He received his MD, PhD degrees from Boston University in 1987. He did his clinical training at Beth Israel Deaconess Medical Center at Harvard Medical School and postdoctoral research at the National Institutes of Health. In 1997, Weissman established his research group at the Perelman School of Medicine at the University of Pennsylvania. He is the Roberts Family Professor in Vaccine Research and Director of the Penn Institute for RNA Innovations...

Nobel Prize - Read more about this year's prize

[Scientific background: Discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19](#)

When SARS-CoV-2 emerged in late 2019 and rapidly spread to all parts of the world, few thought that vaccines could be developed in time to help curb the increasing global disease burden. Yet, several vaccines were approved in record time, with two of the fastest approved and most effective vaccines produced with the new mRNA technology. The concept of using mRNA for vaccination and in vivo delivery of therapeutic proteins was first proposed over 30 years ago, but several hurdles had to be overcome to make this a clinical reality. Early experiments demonstrated that in vitro transcribed mRNA stimulates undesired inflammatory responses and inefficient protein production in cells and tissues. A turning point was the discovery by Karikó and Weissman demonstrating that mRNA produced with modified bases evades innate immune recognition and improves protein expression. These findings, combined with the development of efficient systems for in vivo mRNA delivery, stabilization of the SARS-CoV-2 spike antigen, and unparalleled investments by industry and governments, led to the approval of two highly successful mRNA-based COVID-19 vaccines in late 2020. The discovery by Karikó and Weissman was critical for making the mRNA vaccine

platform suitable for clinical use at a time when it was most needed, making this an extraordinary contribution to medicine and paving the way for future mRNA applications...

.....

Statement on Katalin Karikó and Drew Weissman awarded the Nobel Prize in Medicine 2023

BioNTech Press Release 2 October 2023

All of us at BioNTech applaud Kati (Katalin) Karikó and Drew Weissman on their Nobel Prize in Physiology or Medicine for pioneering nucleoside base modifications, which were one of the key innovations applied to our mRNA-based COVID-19 vaccine. We value both for their passion, persistence, and commitment. This Nobel Prize is a reminder for scientists around the world to continue to engage in rigorous research and development with the great aspiration to unlock the full potential of new drug classes. Gratulálunk and congrats!...

.....

NAM Members Katalin Karikó and Drew Weissman Receive Nobel Prize in Medicine

October 2, 2023

The Nobel Assembly at Karolinska Institutet announced today that they have awarded the 2023 Nobel Prize in Physiology or Medicine jointly to Katalin Karikó and Drew Weissman "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19." Karikó and Weissman were elected to the National Academy of Medicine (NAM) in 2022...

.....

.....

.....

WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization

2 October 2023 *News release Geneva*

The World Health Organization (WHO) has recommended a new vaccine, R21/Matrix-M, for the prevention of malaria in children. **The recommendation follows advice from the WHO: Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Group (MPAG)** and was endorsed by the WHO Director-General following its regular biannual meeting held on 25-29 September.

WHO also issued recommendations on the advice of SAGE for new vaccines for dengue and meningitis, along with immunization schedule and product recommendations for COVID-19. WHO also issued key immunization programmatic recommendations on polio, IA2030 and recovering the immunization programme.

The R21 vaccine is the second malaria vaccine recommended by WHO, following the RTS,S/AS01 vaccine, which received a WHO recommendation in 2021. Both vaccines are shown to be safe and effective in preventing malaria in children and, when implemented broadly, are expected to have high public health impact. Malaria, a mosquito-borne disease, places a particularly high burden on children in the African Region, where nearly half a million children die from the disease each year. Demand for malaria vaccines is unprecedented; however, available supply of RTS,S is limited. The addition of R21 to the list of WHO-recommended malaria vaccines is expected to result in sufficient vaccine supply to benefit all children living in areas where malaria is a public health risk...

Key features of the R21 malaria vaccine:

The updated WHO malaria vaccine recommendation is informed by evidence from an ongoing R21 vaccine clinical trial and other studies, which showed:

- **High efficacy when given just before the high transmission season:** In areas with highly seasonal malaria transmission (where malaria transmission is largely limited to 4 or 5 months per year), the R21 vaccine was shown to reduce symptomatic cases of malaria by 75% during the 12 months following a 3-dose series. A fourth dose given a year after the third maintained efficacy. This high efficacy is similar to the efficacy demonstrated when RTS,S is given seasonally.
- **Good efficacy when given in an age-based schedule:** The vaccine showed good efficacy (66%) during the 12 months following the first 3 doses. A fourth dose a year after the third maintained efficacy.
- **High impact:** Mathematical modelling estimates indicate the public health impact of the R21 vaccine is expected to be high in a wide range of malaria transmission settings, including low transmission settings.
- **Cost effectiveness:** At prices of US\$ 2 – US\$ 4 per dose, the cost-effectiveness of the R21 vaccine would be comparable with other recommended malaria interventions and other childhood vaccines.
- **Similarity of R21 and RTS,S vaccines:** The two WHO-recommended vaccines, R21 and RTS,S, have not been tested in a head-to-head trial. There is no evidence to date showing one vaccine performs better than the other. The choice of product to be used in a country should be based on programmatic characteristics, vaccine supply, and vaccine affordability
- **Safety:** The R21 vaccine was shown to be safe in clinical trials. As with other new vaccines, safety monitoring will continue.

Next steps for the second recommended malaria vaccine, R21/Matrix-M, include completing the ongoing WHO prequalification which would enable international procurement of the vaccine for broader rollout.

At least 28 countries in Africa plan to introduce a WHO-recommended malaria vaccine as part of their national immunization programmes. Gavi, the Vaccine Alliance has approved providing technical and financial support to roll out malaria vaccines to 18 countries. The RTS,S vaccine will be rolled out in some African countries in early 2024, and the R21 malaria vaccine is expected to become available to countries mid-2024...

Note to the editor:

The R21 and RTS,S vaccines act against P. falciparum, the deadliest malaria parasite and the most prevalent on the African continent. The updated WHO recommendation for malaria vaccines was informed by the results of the WHO-coordinated Malaria Vaccine Implementation Programme, through which nearly 2 million children in Ghana, Kenya and Malawi have been reached with the RTS,S/AS01 malaria vaccine since 2019. The pilot introduction of the first malaria vaccine has resulted in a substantial impact in reducing severe malaria illness, hospitalizations and child deaths.

.....

Full Sage Meeting Highlights:

[Highlights from the Meeting of the Strategic Advisory Group of Experts \(SAGE\) on Immunization - 25-29 September 2023](#)

(The full report will be published in the Weekly Epidemiological Record on 1 December 2023, and only the wording of the full report should be considered final)

Session 1

Report from the Department of Immunization, Vaccines, and Biologicals.

- Climate change is accelerating the spread and burden of vaccine-preventable diseases and necessitating modifications in the strategy and implementation of immunization programmes; It has contributed to the backsliding in immunization coverage during the pandemic.
- WHO will be convening stakeholders to identify action necessary to adapt vaccines and immunization programmes for the growing climate threat.
- While there has been significant progress in restoring routine vaccination coverage to pre-pandemic levels, the progress has been uneven, especially in LMICs. Several countries have experienced large and disruptive outbreaks of measles and diphtheria in the last two years.
- Major progress has been made with the COVID-19 vaccination response. Starting in January 2024, the focus will shift to ensuring the annual uptake of vaccination in eligible populations.
- Despite the setbacks experienced during the pandemic, there are opportunities to build back better in the future. Several new vaccines, such as against respiratory disease (respiratory syncytial virus – RSV) or bacterial meningitis and sepsis (group B streptococcus – GBS) are likely to become available in the next five years, which will need to be prioritized for introduction and ensuring access to those most in need.
- Major progress has been made with the COVID-19 vaccination response, and it is critical to continue the progress particularly for those most at risk of disease, including with updates to reporting of coverage.
 - 2024 will be the 50th anniversary of the founding of the Expanded Programme on Immunization (EPI) and a time to celebrate its successes.

Update from Gavi, the Vaccine Alliance.

- As part of the “Big Catch-up”, Gavi reviewed requests for support from 25 countries and will provide flexible financing and technical assistance.
- With the closure of the COVAX Facility in 2023, Gavi will transition to providing support for COVID-19 vaccination to the highest priority groups in eligible countries.
- Gavi is strengthening its role in pandemic prevention, preparedness, and response.
- To address shortfalls in oral cholera vaccine (OCV) supply to mitigate the risk of cholera outbreaks, an OCV market-shaping roadmap was agreed with partners and a UNICEF tender is ongoing for vaccine supply for the period 2024 to 2028.
- The pause in support for vaccines approved in the previous Gavi Vaccine Investment Strategy (VIS) has been lifted and their implementation is underway. The VIS 2024 is underway with a final decision expected by the Gavi Board in June 2024.

Session 2

Dengue

- Dengue poses a significant public health burden in endemic countries and is poised to increase further both in terms of incidence and geographic expansion, due to climate change and urbanization.
- The live-attenuated quadrivalent dengue vaccine developed by Takeda (TAK-003) has demonstrated efficacy against all four serotypes of the virus in baseline seropositive children (4-16 years) in endemic countries and against serotypes 1 and 2 in baseline seronegative children.
- In baseline seronegative children, the vaccine trial did not demonstrate efficacy against symptomatic disease against serotypes 3 and 4 and hospitalization due to serotype 3; there were too few cases of hospitalized serotype 4 cases to assess efficacy. The potential risk of enhanced disease due to serotypes 3 and 4 in seronegative vaccinated children cannot be ruled out.
- SAGE recommended that the vaccine be considered for introduction in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk in seronegative persons.
- SAGE recommended that the vaccine be introduced to children aged 6 to 16 years of age. Within this age range, the vaccine should be introduced about 1-2 years prior to the age-specific peak

incidence of dengue-related hospitalizations. The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.

- SAGE recommended that vaccine introduction should be accompanied by a well-designed communication strategy and community engagement.
- Post-authorization studies should be conducted to further study vaccine effectiveness and safety against serotypes 3 and 4.

Session 3

Antimicrobial resistance

- Modelling studies estimate almost 5 million deaths associated with resistant infections in 2019. However, vaccines remain an underrecognized tool to prevent antimicrobial resistance (AMR).
- WHO evaluated the value of existing and future vaccines on AMR. The analyses indicate that vaccines can have a significant impact on AMR-related health and economic burden and reduce antibiotic use.
- SAGE emphasized that AMR-related endpoints should be included in evaluating vaccines under development and that the evidence on the impact of vaccines on AMR should be considered in policy and investment decisions.

Session 4

Meningitis

- SAGE recommended that all countries in the African meningitis belt introduce the novel pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W and X (Men5CV) into their routine immunization programmes in a single-dose schedule at 9 to 18 months of age.
- In high-risk countries, and countries with high-risk districts, a catch-up campaign should also be conducted at the time of the introduction of Men5CV, targeting all individuals aged 1 to 19 years.
- Countries in the meningitis belt that have already introduced a monovalent meningococcal A conjugate vaccine (MenACV) into their routine programme should switch to Men5CV.
- Countries that have not yet introduced MenACV should do so now and not wait until Men5CV is available, to avoid the risk of a resurgence of *Neisseria meningitidis* serogroup A (NmA).
- Before the planned introduction of Men5CV in immunization programmes, reactive vaccination campaigns may be extended to areas assessed to be at increased risk of an epidemic during the upcoming season.
- The implementation of the recommendation will be instrumental in eliminating epidemic meningitis epidemics in the meningitis belt as envisioned in the 2030 global WHO road map.

Session 5

Immunization Agenda 2030 (IA2030)

- SAGE was presented with the technical progress report, which was developed through a collaborative, multi-stakeholder process and reviewed and endorsed by the Immunization Agenda Coordination Group.
- Progress against the IA2030 indicators was stalled due to the impact of the COVID-19 pandemic and was off-track for six of the seven impact goal targets; progress against the target for the introduction of new vaccines is on track driven by the introduction of new vaccines in low-income countries in 2022.
- While there are promising signs of recovery, it is uneven; recovery is especially slow in low-income countries and vulnerable populations living in fragile and conflict-affected settings.
- Low coverage of measles-containing vaccines has increased the risk of large, disruptive outbreaks.
- Beyond the time-limited campaigns as one part of the "Big Catch-up", sustained efforts to fill immunity gaps are required in the immediate and long term through strengthening of immunization programmes within primary health care and along the life-course. The aim is to restore immunization programme performance to pre-pandemic levels (2nd objective of the Big Catch-up)

and to do more to get onto the trajectory needed to achieve the 2030 goals (3rd objective of the Big Catch-up).

- A shared action agenda for 2023-2024 that sets out a series of short-term and high-level priorities to align the efforts of countries, regions, global partners, and other stakeholders has been developed and SAGE was invited to provide feedback on this action agenda.
- The action agenda has six trajectories, which are catch-up and strengthening of immunization programmes, equity promotion, regaining control of measles, making the case for investment into immunization, accelerating the introduction of WHO-recommended vaccines, and advancing vaccination in adolescence.

Session 6

Poliomyelitis

- SAGE was pleased to note that wild poliovirus type 1 (WPV1) circulation is confined to a small geographic area at the border between Afghanistan and Pakistan and with lower genetic diversity between isolates.
- SAGE expressed concern about the continued detection of circulating vaccine-derived poliovirus (cVDPV) type 2 (cVDPV2) in Africa and increasing detection of cVDPV type 1 in several countries and stressed the need for efforts to improve routine immunization coverage; routine immunization is the means by which most polio vaccines are delivered and hereby establish individual and population-based immunity.
- SAGE recommended that to minimize the risk of seeding new cVDPV2 outbreaks, the novel oral poliovirus vaccine type 2 (nOPV2) should be used in high-quality campaigns with a maximum interval of 4 weeks between campaign rounds.
- SAGE recommended that in areas of type 1 and 2 poliovirus cocirculation, sequential vaccination campaigns with nOPV2 and bivalent OPV (bOPV) should be implemented; short intervals between homologous vaccines should be considered.

Session 7

Malaria

- In a joint session, SAGE and the Malaria Policy Advisory Group (MPAG) reviewed the available evidence on the novel malaria vaccine R21/Matrix-M.
- The R21/Matrix-M vaccine is similar to the RTS,S/AS01 malaria vaccine and there is no evidence that one vaccine performs better than the other.
- SAGE and MPAG recommended that either the R21/Matrix-M or RTS,S vaccine be used for the prevention of *P. falciparum* malaria in children living in malaria-endemic areas, prioritizing areas of moderate and high transmission but also considering vaccination in low transmission settings.
- Vaccine introduction should be done in the context of comprehensive malaria control efforts.
- The R21/Matrix-M vaccine should be administered in a 4-dose schedule from 5 months of age, as recommended for RTS,S; a 5th dose may be considered in areas where there is a significant malaria risk remaining in children who have received four doses.
- The availability of this second malaria vaccine is expected to close the gap between supply and demand, enabling broader and possibly unconstrained access; malaria vaccines introduced widely have the potential to save tens of thousands of young lives each year.

Session 8

Smallpox

- SAGE was presented with the results of a systematic review of the available data on the safety and efficacy of Smallpox vaccines, including the second and third-generation vaccines; no data were available for the fourth-generation orthopoxvirus vaccine.
- First-generation vaccines have higher rates of serious adverse events and myocarditis.
- SAGE recommended the addition of the third-generation MVA vaccine to the WHO reserve in addition to the existing vaccines.

- Primary prevention through vaccination is recommended for laboratory personnel handling orthopoxviruses, and outbreak response teams. Revaccination may be administered as often as every 3 to 5 years for laboratory workers at the highest risk. The need and frequency of re-vaccination of other high-risk groups need to be determined.
- In the case of outbreak response, targeted vaccination is recommended for contacts and other persons at risk of infection. Second and third-generation vaccines are recommended for outbreak response. When these are not available, first-generation can be considered. Vaccination should not be withheld from previously vaccinated persons. Large-scale mass vaccination is not recommended.
- Immunocompromised or pregnant persons and caregivers or close contacts of such persons should receive non-replicating vaccines.

Session 9

COVID-19

- SAGE was presented with updated data on the epidemiology of COVID-19, including death rates among priority-use groups; vaccine effectiveness data during Omicron XBB sub-lineages circulation; and pre-clinical and clinical data on novel monovalent XBB vaccines.
- Based on the data reviewed, SAGE recommended a simplified single-dose regime for primary immunization for most COVID-19 vaccines which would improve acceptance and uptake and provide adequate protection at a time when most people have had at least one prior infection.
- Available data suggest the monovalent Omicron XBB vaccines provide modestly enhanced protection compared to bivalent variant-containing vaccines and monovalent index virus vaccines.
- When monovalent XBB vaccines are not available, any available WHO emergency-use listed or prequalified vaccine, bivalent variant-containing or monovalent index virus vaccines, may be used since they continue to provide benefits against severe disease in high-risk groups.
- SAGE approved an updated roadmap for COVID-19 vaccination that reflects the simplified schedule, updated recommendations on revaccination and the currently available COVID-19 vaccines.

Session 10

Mumps

- Most countries have introduced mumps vaccination through the use of the measles-mumps-rubella combination (MMR) vaccine.
- While associated with significant short-term morbidity, the most severe complication – encephalitis – occurs with a similar frequency and at a similar age as measles. Mumps is a significant cause of long-term hearing loss.
- The available evidence indicates that the mumps vaccines in use are safe and effective and that mumps is well controlled in all countries with sustained high coverage.
- In low- and middle-income countries, data on the burden and epidemiology of mumps is scarce and the incremental cost of the MMR vaccine over the measles-rubella (MR) vaccine is substantial.
- SAGE therefore recommended a careful review of the uncertainties, risks and programmatic implications when considering the introduction of mumps-containing vaccines in LMICs.
- Countries that introduce the mumps vaccine should provide it in combination with measles and rubella as MMR vaccine delivered using the same schedule as for MR vaccines and maintain high coverage as recommended for MR vaccines which will mitigate the risk of a shift in age-specific incidence of infection.
- Countries that introduce the mumps vaccine should enhance surveillance to demonstrate the impact of the vaccine and monitor epidemiological shifts.

Session 11

Cholera

- Since 2021, cholera outbreaks have become more frequent, larger and more deadly with a strong link to climate change.

- SAGE reinforced its 2017 recommendation that all relevant target groups for vaccination in OCV campaigns, including pregnant women, be considered for vaccination.
- SAGE expressed its deep concern about the continuing supply constraints of the oral cholera vaccine (OCV) and asked that strategies for mitigating the impact of these supply shortfalls be accelerated.
- Based on an assessment of evidence, SAGE acknowledged the public health benefit of the use of the killed whole cell bivalent (O1, O139) OCV (EuBiologics) under controlled temperature chain (CTC) conditions of not more than 10 days at ambient temperatures not exceeding 40°C.



[The African Union Vaccine Manufacturing member states ministers of health and their representatives Gathered for the first manufacturers’ marketplace meeting and inaugural ministerial working group in Marrakech, Morocco, from 29 September 2023 to 1 October 2023](#)

Communiqué 4 October 2023

The meeting was represented by eleven (11) of the thirteen (13) vaccine manufacturing Member States: Botswana, Egypt, Ethiopia, Ghana, Kenya, Morocco, Nigeria, Senegal, South Africa, Rwanda, and Uganda, including National Regulatory Authorities (10), African Continental Free Trade Area (AfCFTA), Regional Economic Communities (3), Gavi, UNICEF and UNECA and manufacturers from potential African vaccine manufacturing countries. The delegates deliberated on the submission by Africa CDC and UNECA on the proposed Legal Instrument for the adoption of AU Pooled Procurement Mechanism (PPM)...

The meeting recommended the following next steps:

1. A Framework Agreement for pooled procurement of vaccines, medicines, and other health products shall be prepared by the Africa CDC to facilitate the pilot pooled procurement mechanism for vaccines while awaiting a legal instrument to expand regional health product manufacturing. The framework will be submitted to the Africa CDC Governing Board and the Committee of the Heads of State and Government for approval, while the draft legal instrument will be tabled for approval at the next AU Summit in February 2024.

2. The framework can be administered through Service Level Agreements, which can be tailored to individual Member States or manufacturers when the need arises. These Service Level Agreements shall;

- (a) Encourage regional manufacturing of good quality vaccines, medicines, and other health products in African Union Member States;
- (b) Ensure uniformity in the contract for the pooled procurement. The contract shall include transparent clauses about pricing, quantities, production and delivery timelines, rights and liabilities, and conflicts of interest.
- (c) Ensure timely access to vaccines; AU Member States shall focus on infrastructure and digitalization for efficient acquisition and distribution;
- (d) Establish a specific funding mechanism, along with the utilization of existing financing arrangements, to support the relevant investment and procurement of essential medical supplies;
- (e) Invest in developing local technical skills with continuous training and promoting collaboration between the manufacturers and regulators.

3. The Africa CDC will prepare and implement an activity rollout plan for the negotiations for a legally binding instrument to:

- (a) Resolve to develop the “Common African Legal Instrument for Pooled Procurement of Vaccines, Medicines, and Other Health Products” under the African Union Legal framework;
- (b) Advocate for global partners to join in seizing this unprecedented opportunity to accelerate regional manufacturing;
- (c) Call Upon WHO to support and expedite the Prequalification of African manufactured products to enable donor-funded markets for vaccines, medicines, and other health products;
- (d) Urge Gavi and UNICEF to consider alternative prequalification processes, such as recognized African regulatory authorities at maturity level 3, that provide adequate processes to ensure the safety and quality of vaccines;

4. Call Upon the Heads of State and Government to approve the roadmap for the Platform for Harmonized African Health Products Manufacturing (PHAHM) to be developed by Africa CDC, to ensure the expansion of regional manufacturing for all health products;

5. Uphold the principles stated in this Communiqué by ensuring and advocating for alignment with domestic legislation.



[Preparing for the Next Pandemic Will Require Better Global Governance, Argues New CFR Report – Council of Foreign Relations](#)

News Releases October 5, 2023

“The challenges to global health are numerous and multiple factors make the emergence and spread of another virulent pathogen not only possible but also probable,” warns a new *Council Special Report* by [Yanzhong Huang](#) and Rebecca Katz.

“[T]he window of opportunity for enhancing pandemic preparedness is rapidly diminishing,” caution Huang, senior fellow for global health at the Council on Foreign Relations, and Katz, director of the Center for Global Health Science and Security at Georgetown University.

The new report, *Negotiating Global Health Security: Priorities for U.S. and Global Governance of Disease*, asserts: “In the face of unprecedented global challenges, three crucial tasks emerge as paramount: promoting public health capabilities, bridging the gaps in global health governance, and effectively mitigating the harmful effects of geopolitical tensions.” [Report PDF](#)

While the authors acknowledge well-known global health threats, there are also other contributing factors. They note that climate change increases “the likelihood of contact between disease-carrying animals and humans” and underscore that vulnerabilities in the global supply chain threaten “the production, distribution, and delivery of the medical supplies and commodities essential to global health security.”

“Global health security and pandemic preparedness and response are at a critical juncture,” the authors write. “The goal is not to find the perfect governance structure, but rather to establish robust implementation frameworks and secure the necessary financing to ensure effective functionality when faced with the next pandemic.”

The authors suggest that countries take three critical steps:

- **“promote public health capabilities”** by “building foundational country-level capacity, investing in medical countermeasures, and supporting regional centers for public health.”

- “**close the gaps in global health governance,**” which includes “countering misinformation and disinformation, and responding to deliberate biological events and complex health emergencies.”
- “**mitigate the harmful effects of geopolitical rivalries**” to mobilize “[g]lobal collective action against health threats.”

“As countries emerge from the acute phase of the COVID-19 pandemic, multiple opportunities exist to address the challenges laid bare during the past three years and to build stronger, more equitable, and sustainable systems,” Huang and Katz highlight. “It is imperative to take swift actions to address the significant capacity and governance gaps in global health security before another major epidemic or pandemic arises,” they conclude.

To read *Negotiating Global Health Security: Priorities for U.S. and Global Governance of Disease*, visit cfr.org/global-health-security.

:::::
:::::

Public Consultations/Call for Papers

[Call for Contributions - OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products \(HRC resolution 50/13\)](#)

Office of the High Commissioner for Human Rights | Call for input | Treaty bodies

Deadline: 30 November 2023

Purpose:

To inform the OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products (HRC resolution 50/13)

Background:

Vaccine equity and access to medicines is a fundamental component of the full realization of the right to health. Vaccines, medicines and other health products must not only be produced and made available - they must also be accessible to all persons. Yet, access to vaccines, medicines and other health products remains disturbingly uneven in many places.

Council resolution 50/13 requests the Office of the High Commissioner for Human Rights (OHCHR) to prepare an analytical study on key challenges in ensuring access to medicines, vaccines and other health products to be presented to the Human Rights Council at the fifty-sixth session in June 2024. In order to collect inputs for this forthcoming report, OHCHR has published a short questionnaire available in [English](#), [Français](#) and [Español](#).

[Establishing the impact of WHO’s normative and standard-setting functions: a call for papers](#)

Editorial

Lisa M Askie, Rebekah AL Thomas, Rok Ho Kim, Mubashar Sheikh, Jeremy Farrar
Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

doi: 10.2471/BLT.23.290829

PMCID: PMC10523809

The deadline for submissions is 1 March 2024

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,⁶ the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and

capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,⁷ and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

...Manuscripts should be submitted in accordance with the Bulletin's guidelines for contributors (available at: <https://www.who.int/publications/journals/bulletin/contributors/guidelines-for-contributors>) and the cover letter should mention this call for papers. This theme issue will be published in the October 2024 issue of the Bulletin, to coincide with the annual World Evidence-Based Health Care Day on 20 October 2024.

.....
.....

Polio – PHEIC

[Polio this week as of 04 Oct 2023](#) - GPEI

Headlines [Selected]

:: In the lead-up to World Polio Day on 24 October, GPEI has launched a *Make Polio History* campaign to rally existing and new supporters of polio eradication from all over the world to champion the cause. We need your help! Add your voice in support of eradication by visiting the [campaign website](#) and taking action.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: one WPV1 case
- Pakistan: seven WPV1 positive environmental samples
- Cameroon: one cVDPV2 positive environmental sample
- Chad: three cVDPV2 cases and one positive environmental sample
- DR Congo: one cVDPV2 case
- Kenya: two cVDPV2 positive environmental samples
- Madagascar: eight cVDPV1 positive environmental samples
- Nigeria: one cVDPV2 positive environmental sample
- Somalia: one cVDPV2 positive environmental sample



Coronavirus [COVID-19]

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

WHO Weekly Epidemiological and Operational updates

Last update: 27 September 2023

Confirmed cases :: 771 151 224

Confirmed deaths :: 6 960 783

Vaccine doses administered: 13 513 017 637




Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 07 Oct 2023]

- [70.5%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- [13.51 billion doses](#) have been administered globally, and [32,559](#) are now administered each day.
- [32.6%](#) of people in low-income countries have received at least one dose.

Daily COVID-19 vaccine doses administered

7-day rolling average. All doses, including boosters, are counted individually.



MPOX

<https://www.who.int/emergencies/situation-reports>

Latest Report

[Multi-country outbreak of mpox, External situation report#28 – 19 September 2023](#)

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

WHO & Regional Offices [to 07 Oct 2023]

<https://www.who.int/news>

Selected News/Announcements/Statements

8 October 2023 Departmental news

[EVIPNet and University College London launch new project to pilot the WHO checklist on EIPM institutionalization](#)

The World Health Organization (WHO), the [Evidence for Policy & Practice Information and Coordination Centre \(EPPI-Centre\)](#) at University College London, and the [Special Programme for Research and Training in Tropical Diseases \(TDR\)](#) are jointly launching a new project on piloting a checklist for the institutionalization of evidence-informed policy-making (EIPM).

This [checklist](#) was developed in 2023 and aims at assisting countries in planning, monitoring, evaluating, and learning about their EIPM institutionalization process. However, this tool has seen limited application in practice, leading to a need to test its validity and feasibility in the real world...

7 October 2023 News release

[Governments make progress towards agreeing amendments to the International Health Regulations \(2005\)](#)

Progress was made this week on many of the over-300 proposed amendments to the International Health Regulations 2005 (IHR). In this fifth round of intensive discussions, taking place under the aegis of the Working Group on Amendments to the IHR (WGIHR) – which includes the 196 States Parties to the IHR, the European Union and the Observer Delegation of Palestine...

5 October 2023 Departmental news

[Quadripartite launches the Working Group on Youth Engagement for Antimicrobial Resistance](#)

5 October 2023 Departmental news

[Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - September 2023](#)

2 October 2023 News release

[WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

[WHO African Region](#)

No new digest content identified.

WHO Region of the Americas PAHO

:: 4 Oct 2023

[PAHO seeks to strengthen pharmaceutical services in the Americas](#)

Buenos Aires, 4 October 2023 (PAHO)- The Pan American Health Organization (PAHO) today presented a new tool to assess the quality of pharmaceutical service provision and launched a network to share information and facilitate collaboration among countries. This aims to improve the quality of pharmacies in the Region through the primary health care...

:: 3 Oct 2023

[PAHO Director meets with President of Argentina to discuss regional vaccine development and other priority health issues](#)

Buenos Aires, 3 October 2023 (PAHO/WHO) – The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, today met with the President of Argentina, Alberto Fernandez, where they discussed the need to strengthen the production of vaccines and medical supplies in Latin America and the Caribbean in order to ensure regional self-...

:: 2 Oct 2023

[PAHO advances technical cooperation with Argentina to strengthen regional production of mRNA vaccines](#)

Under the new agreement, the National Administration of Laboratories and Health Institutes (ANLIS-Malbrán) will develop lipid nanoparticles, essential elements for national vaccine production. Buenos Aires, 2 October 2023 (PAHO)- The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa today signed a new agreement with...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 5 October 2023 News release

["What is wrong with me?" Children face a frustrating lack of answers about long COVID](#)

:: 4 October 2023 News release

[Restoring access to primary health care in war-torn areas: WHO installs modular facilities to serve Ukraine's frontline communities](#)

:: 1 October 2023 Statement

[Racing to meet the health needs of refugees entering Armenia](#)

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Multi-country outbreak of cholera, External situation report #7 - 5 October 2023

Overview

Since the last situation report on the multi-country outbreak of cholera was published on 6 September 2023 (covering data reported until 15 of August), and as of 15 September 2023, a new outbreak of acute watery diarrhoea (AWD) was reported from Iraq. In total, 29 countries have reported cases since the beginning of 2023. The WHO African Region remains the most affected region with 16 countries reporting cholera cases since the beginning of the year. The overall capacity to respond to the multiple and simultaneous outbreaks continues to be strained due to the global lack of resources, including shortages of the oral cholera vaccine and cholera supplies, as well as overstretched public health and medical personnel, who are dealing with multiple parallel disease

outbreaks and other health emergencies. Based on the large number of outbreaks and their geographic expansion, as well as a lack of vaccines and other resources, WHO continues to assess the risk at global level as very high.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

3 October 2023 | Nipah Virus Infection - India

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 98, No. 40, pp. 471–488

6 October 2023

PDF: <https://iris.who.int/bitstream/handle/10665/373227/WER9840-eng-fre.pdf>

Contents

471 Global leishmaniasis surveillance: past ten years

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

6 October 2023

Global leishmaniasis surveillance, 2022: assessing trends over the past 10 years

6 October 2023

mhGAP Humanitarian Intervention Guide (mhGAP-HIG) training of health-care providers

5 October 2023

Guidance for country validation of viral hepatitis elimination and path to elimination

4 October 2023

WHO Expert Committee on Biological Standardization. Seventy-seventh report

3 October 2023

Strategies to facilitate sharing of technology and knowledge through WHO COVID-19 Technology Access Pool

Overview

The COVID-19 Technology Access Pool (C-TAP), originally proposed by Costa Rica, is a multi-partner initiative established in May 2020 to accelerate the development, manufacture and global distribution of products to diagnose, prevent and treat COVID-19. Sharing of information, knowledge, data and other resources greatly accelerates product development and avoids duplication of efforts. The C-TAP platform facilitates such sharing for the development of products for public health.

At the time of writing, two technology holders, public institutions in Spain and the USA, had entered into licensing agreements with the C-TAP for inventions and candidate products, including

vaccines. The C-TAP could be expanded if other technology holders made similar contributions. To promote further engagement of technology holders with the C-TAP, the WHO secretariat administered a questionnaire for Member States to identify legislation, regulations, guidelines and procedures that could be amended or introduced to encourage sharing of technology. Thirty-eight Member States submitted responses to the C-TAP questionnaire. The purpose of this report is to summarize the responses made to the C-TAP questionnaire...

2 October 2023

[Strategic and technical advisory group for tuberculosis: annual meeting report, 3–5 July 2023](#)

1 October 2023

[Ethics and adaptive platform trial design in public health emergencies: meeting report, 18-19 July 2022](#)

Overview

Platform trials using adaptive methods have played a key role in the research response to COVID-19. They raise important ethical issues, however, associated not only with the methods used but also with their scale, their global nature and their probable contribution to pandemic preparedness. This report summarizes the discussions at a 2-day meeting on the findings of five rapid reviews on the ethical aspects of adaptive platform trials after the first 2 years of the COVID-19 pandemic. Cross-cutting themes included the importance of “lean” project management and of pre-pandemic preparedness, particularly in forming trusted relationships in international networks; challenges to meaningful community engagement, ethics review and participant consent; questions of inclusion and the implications for equitable access; factors that influence the fairness and sustainability of international partnerships, including capacity development and knowledge transfer; and governance arrangements that ensure both local and global accountability. Remaining evidence gaps were identified. This report summarizes the key themes that emerged from the review presentations and the subsequent discussion.

.....

USA – HHS, FDA, CDC

HHS

News

[HHS Releases Notice of Proposed Rulemaking to Update 2005 Public Health Service Policies on Research Misconduct](#)

October 5, 2023 *News Release*

FDA

Press Announcements

October 3, 2023 - **[FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants](#)**

FDA VRBPAC

Advisory Committee Calendar

No new meetings scheduled.

CDC/ACIP [U.S.] [to 07 Oct 2023]

<http://www.cdc.gov/media/index.html>

Latest News Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

October 25-27.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

October 6, 2023 / No. 40

[PDF of this issue](#)

- [Characteristics and Outcomes Among Adults Aged ≥60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus — RSV-NET, 12 States, July 2022–June 2023](#)
- [Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023](#)
- [COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023](#)
- [Disparities in COVID-19 Vaccination Status Among Long-Term Care Facility Residents — United States, October 31, 2022–May 7, 2023](#)



Europe

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/search/search/ema_editorial_content/ema_news?sort=field_ema_computed_date_field&order=desc

News & Press Releases

[News: Revised transparency rules for the EU Clinical Trials Information System \(CTIS\) \(new\)](#)

Last updated: 06/10/2023



European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports [Selected]

News

[Weekly COVID-19 country overview](#)

Epidemiological update - 5 Oct 2023

[Sweden's advice-making process on schools during the COVID-19 pandemic: Good practices and lessons learnt](#)

Press release - 4 Oct 2023

Latest publications

[Communicable disease threats report, 1-7 October 2023, week 40](#)

Monitoring - 6 Oct 2023

[Eleventh external quality assessment scheme for typing of Shiga toxin-producing Escherichia coli](#)

External quality assessment - 5 Oct 2023

The Swedish advice-making process for distance learning in schools, November 2020 – April 2021

Assessment - 4 Oct 2023

Core protocol for ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection at primary care level

Guidance - 3 Oct 2023

.....
.....

Africa CDC [to 07 Oct 2023]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

Statement

Mastercard Foundation and Africa CDC Remain Committed to Saving Lives and Livelihoods

5 October 2023

Communiqué

The African Union Vaccine Manufacturing member states ministers of health and their representatives Gathered for the first manufacturers' marketplace meeting and inaugural ministerial working group in Marrakech, Morocco, from 29 September 2023 to 1 October 2023

4 October 2023

[Full post-meeting statement]

Press Releases

African vaccine manufacturing capacity

Form/fill/finish capacity is strong while end-to-end local vaccine production will require additional investment.

Addis Ababa, Ethiopia; Boston, MA, USA; Seattle, WA, USA, 03 October 2023 – The Africa Centres for Disease Control and Prevention (Africa CDC), the Clinton Health Access Initiative (CHAI), and PATH have released a new briefing paper, "Current and planned vaccine manufacturing in Africa," following an assessment of vaccine manufacturing capacity in Africa. ...

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 07 Oct 2023]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 07 Oct 2023]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC Weekly Reports: Current Volume (5)
2023-10-06 / No. 40 *WORLD MENTAL HEALTH DAY ISSUE*

[View PDF of this issue](#)

- [Preplanned Studies: The Long-Term Impacts of COVID-19 on Physical and Psychological Health — Beijing Municipality, China, December 2022–April 2023](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, June 2023*](#)



Contents *[click to move among sections]*

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)



Organization Announcements

Paul G. Allen Frontiers Group [to 07 Oct 2023]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 07 Oct 2023]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 07 Oct 2023]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 07 Oct 2023]

<https://carb-x.org/>

News

10.03.2023 |

[CARB-X IS FUNDING A UNIVERSITY OF MELBOURNE RESEARCH TEAM TO DEVELOP AN ORAL THERAPEUTIC TO TREAT DRUG-RESISTANT COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA](#)

CARB-X is awarding US\$1.75 million to the University of Melbourne at the Doherty Institute to develop an oral therapeutic that restores the activity of workhorse antibiotics used to treat community-acquired bacterial pneumonia (CABP).

CEPI – Coalition for Epidemic Preparedness Innovations [to 07 Oct 2023]

<http://cepi.net/>

Latest News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 07 Oct 2023]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 07 Oct 2023]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 07 Oct 2023]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 07 Oct 2023]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

03 October 2023

[WHO recommends R21/Matrix-M malaria vaccine](#)

03 October 2023

[Dr Michael Makanga named new Executive Director of the Global Health EDCTP3 Joint Undertaking](#)

Emory Vaccine Center [to 07 Oct 2023]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 07 Oct 2023]

<http://www.euvaccine.eu/>

Latest News, Events
No new digest content identified.

Evidence Aid [to 07 Oct 2023]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[Sexual and reproductive health interventions during humanitarian crises](#)

Added October 5, 2023

Fondation Merieux [to 07 Oct 2023]

<http://www.fondation-merieux.org/>

News, Events

Project

[Introducing PCV and rotavirus vaccine in Chad, Guinea, Somalia, and South Sudan Workshop](#)

October 6, 2023 - N'djamena (Chad)

The Mérieux Foundation, Every Breath Counts, the Malaria Consortium, the International Vaccine Access Center (IVAC), and Save the Children, in partnership with the Chad Ministry of Public Health and Prevention hosted an in person Workshop, to support the governments of Chad, Guinea, Somalia, and South Sudan after they expressed their commitment to introducing two of the most powerful vaccines for children - the pneumococcal conjugate vaccine and rotavirus vaccine...

Gavi [to 07 Oct 2023]

<https://www.gavi.org/>

News Releases

4 October 2023

[Life-saving HPV vaccine introduced nationwide into routine immunisation schedule to prevent cervical cancer in Cambodia](#)

4 October 2023

[Africa CDC & Gavi, the Vaccine Alliance host the First Manufacturers Marketplace for Vaccine Manufacturing African Union Member States](#)

... The meeting aimed at:

- Gathering African vaccine manufacturers, their Health and Finance Ministers and National Regulatory Authorities, to identify the best modalities for achieving the success and the sustainability of the on-going manufacturing projects;
- Creating awareness among participating member states about the importance of their commitments to select and procure from African manufacturers;
- Creating a platform for manufacturers to present their current vaccine capacity and expansion plans, and discuss how these could help direct/build on market shaping activities;
- Exchanging views on the design of Gavi's proposed African Vaccine Market Accelerator (AVMA) an instrument seeking approximately US \$1 billion of financing, which aims to support sustainable vaccine manufacturing in Africa by offsetting initial costs and enabling competitive entry into the market. The potential AVMA will be considered by the Gavi Board later this year; and
- Sharing best practices for a strengthened private – public partnership.

4 October 2023

[The Government of Bangladesh launches nationwide human papillomavirus \(HPV\) vaccination campaign](#)

Supported by UNICEF, Gavi, the Vaccine Alliance and WHO, the campaign will protect girls and women against cervical cancer

2 October 2023

[RBM Partnership to End Malaria welcomes WHO's recommendation of world's second malaria vaccine](#)

Global malaria community calls for increased investment in development and scale-up of malaria innovations following R21 vaccine announcement – but RBM Partnership warns "it's not the only solution".

GE2P2 Global Foundation [to 07 Oct 2023]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – October 2023](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Sep 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 06 Oct 2023 – Issue 08](#)

GHIT Fund [to 07 Oct 2023]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 07 Oct 2023]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 07 Oct 2023]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 07 Oct 2023]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 07 Oct 2023]

<https://www.hhmi.org/news>

Press Room

Research Oct 4 2023

[How Tubular Bacterial Weapons Compromise Plant Cells to Cause Disease](#)

Microbes flood leaves and then proliferate in the water-logged patches. New research answers a long-standing question about just how this happens and points toward a potential countermeasure.

Human Vaccines Project [to 07 Oct 2023]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 07 Oct 2023]

<https://www.iavi.org/>

Latest News

No new digest content identified.

INSERM [to 07 Oct 2023]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 07 Oct 2023]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

[Public Consultation: ICH E6\(R3\) Principles, Annex 1 and Annex 2](#)

The E6(R3) EWG is working on the revision of the E6(R2) Guideline "Good Clinical Practice" (GCP) with a view to addressing the application of GCP principles to the increasingly diverse trial types and data sources being employed to support regulatory and healthcare related decision-making on drugs, and provide flexibility whenever appropriate to facilitate the use of technological innovations in clinical trials. Additional information may also be found in ICH Reflection Paper on "GCP Renovation" on the [ICH Reflection Paper page](#). When complete, E6(R3) will be composed of an overarching principles and objectives document, Annex 1 and Annex 2.

[E6\(R3\) Draft Guideline](#)

Remaining public consultation dates:

Health Canada, Canada - Deadline for comments by 20 October 2023

ICRC [to 07 Oct 2023]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 07 Oct 2023]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Press release 29/09/2023

[IFRC launches 20 million Swiss Francs appeal to support people on the move in Armenia](#)

Press release 28/09/2023

[Red Cross responding to major humanitarian needs as tens of thousands cross into Armenia](#)

Institut Pasteur [to 07 Oct 2023]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release 03.10.2023

[The Institut Pasteur & the University of Tokyo have signed a LOI to establish the Planetary Health Innovation Center, marking the first step towards the Institut Pasteur of Japan](#)

ISC / International Science Council [to 07 Oct 2023]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 07 Oct 2023]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 07 Oct 2023]

<http://www.ivi.int/>

IVI News & Announcements

[Profs. Katalin Karikó and Drew Weissman, recipients of 2022 IVI – SK bioscience Park MahnHoon Award, named 2023 Nobel laureates in Physiology or Medicine](#)

Oct 4,, 2023

Johns Hopkins Center for Health Security [to 07 Oct 2023]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 07 Oct 2023]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine - USA [to 07 Oct 2023]

<https://nam.edu/programs/>

News [Selected]

[Statement on NAM Commitment to Reducing Greenhouse Gas Emissions](#)

October 4, 2023

The National Academy of Medicine (NAM) is fully committed to the reduction of emissions of CO₂ and other greenhouse gases as the single most important step all organizations must take [...]

[National Academy of Medicine Announces 10 Emerging Leaders in Health and Medicine](#)

October 3, 2023

The National Academy of Medicine (NAM) today announced the 2023 Emerging Leaders in Health and Medicine Scholars. These individuals are early- to mid-career professionals from a wide range of health-related fields...

The 2023 Emerging Leaders in Health and Medicine Scholars are:

- Adewole S. Adamson, MD, MPP, assistant professor of internal medicine, Division of Dermatology, Dell Medical School, University of Texas at Austin
- Peter Croughan, MD, addiction medicine physician, Acadiana Area Human Services District; and clinical assistant professor of medicine, Louisiana State University
- Cesar de la Fuente, PhD, presidential assistant professor, University of Pennsylvania
- Elizabeth M. Cespedes Feliciano, ScD, ScM, research scientist, Kaiser Permanente Northern California Division of Research
- Celine Gounder, MD, senior fellow and editor-at-large for public health, KFF Health News; medical contributor, CBS News; and clinical associate professor of medicine and infectious diseases, NYU Grossman School of Medicine and Bellevue Hospital
- Jerreed D. Ivanich, PhD, assistant professor, Centers for American Indian and Alaska Native Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus
- Lucinda B. Leung, MD, PhD, MPH, assistant professor of medicine and psychiatry, David Geffen School of Medicine at the University of California, Los Angeles, and West Los Angeles VA Medical Center
- Akinyemi Oni-Orisan, PharmD, PhD, assistant professor, University of California, San Francisco
- Anita Shukla, PhD, associate professor, Brown University School of Engineering
- Judy Wawira Gichoya, MBChB, MS, assistant professor of radiology, Emory University

[NAM Members Katalin Karikó and Drew Weissman Receive Nobel Prize in Medicine](#)

October 2, 2023

The Nobel Assembly at Karolinska Institutet announced today that they have awarded the 2023 Nobel Prize in Physiology or Medicine jointly to Katalin Karikó and Drew Weissman "for their discoveries concerning nucleoside base modifications that enabled the development of effective

mRNA vaccines against COVID-19." Karikó and Weissman were elected to the National Academy of Medicine (NAM) in 202 The Nobel Assembly at Karolinska Institutet announced today that they have awarded the 2023 Nobel Prize in Physiology or Medicine jointly to Katalin Karikó and Drew Weissman "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19." Karikó and Weissman were elected to the National Academy of Medicine (NAM) in 2022..

National Academy of Sciences - USA [to 07 Oct 2023]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 07 Oct 2023]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 07 Oct 2023]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 07 Oct 2023]

<https://www.path.org/media-center/>

Press Releases

[PATH statement on the high-level meetings at the 78th United Nations General Assembly](#)

October 5, 2023 by PATH

PATH commends Member States and the international community for reaffirming their commitments to health through their political declarations, recognizing the challenges that persist and the opportunities to accelerate progress in achieving universal health coverage, ending TB, and preventing, preparing for, and responding to future pandemics...

Rockefeller Foundation [to 07 Oct 2023]

<https://www.rockefellerfoundation.org/>

Selected Reports/Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 07 Oct 2023]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 07 Oct 2023]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

Press statement

[UNAIDS welcomes new decision in Colombia allowing more affordable access to quality HIV medicines](#)

Colombia makes landmark decision to declare the HIV medicine dolutegravir of public interest, allowing the country to purchase or manufacture more affordable, generic versions of the live-saving HIV medicine

4 October 2023

UNICEF [to 07 Oct 2023]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 06 October 2023

[Weather-related disasters led to 43.1 million displacements of children over six years - UNICEF](#)

<https://www.unicef.org/press-releases/weather-related-disasters-led-431-million-displacements-children-over-six-years>

NEW YORK, 6 October 2023 – Weather-related disasters caused 43.1 million internal displacements of children in 44 countries over a six-year period – or approximately 20,000 child displacements a day - according to a new UNICEF analysis released today. Children Displaced in a Changing Climate is the first global analysis of the number of children...

Unitaid [to 07 Oct 2023]

<https://unitaid.org/>

Featured News

02 October 2023

[Unitaid welcomes J&J's announcement not to enforce patents for vital TB drug](#)

Unitaid applauds Johnson & Johnson's decision, announced Friday 29 September, not to enforce its secondary patents for bedaquiline, a critical medicine for treating drug-resistant tuberculosis (DR-TB). The decision will affect people in 134 low- and middle-income countries, many of which have the highest burden of disease and have struggled to supply the critical medicine due to high costs...

02 October 2023

[World Oxygen Day](#)

In our new [Issue Brief](#), we explain how Unitaid is working with partners to ensure equitable, sustainable access to medical oxygen for the people who need it most. From introducing innovative new devices to provide oxygen to newborns who are struggling to breathe to negotiating cost-saving new deals with liquid oxygen suppliers, we're responding to today's crises while helping build sustainable systems that will save millions more lives in the future.

Vaccine Equity Cooperative [nee Initiative] [to 07 Oct 2023]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 07 Oct 2023]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 07 Oct 2023]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 07 Oct 2023]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 07 Oct 2023]

<https://wellcome.ac.uk/news>

News, Opinion, Reports

Analysis

Author - Charlie Weller

[Childhood immunisation is recovering, but there’s a long way to go](#)

4 October 2023

20.5 million children hadn’t received essential vaccinations in 2022, according to the latest data from the World Health Organization (WHO) and UNICEF. While that marks an improvement to 2021, coverage still falls short of pre-pandemic levels for many countries.

The Wistar Institute [to 07 Oct 2023]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 07 Oct 2023]

<https://www.wfpha.org/>

Latest News - Blog

No new digest content identified.

World Medical Association [WMA] [to 07 Oct 2023]

<https://www.wma.net/news-press/press-releases/>

Press Releases

[Gender Equality In Healthcare Is A Top Priority, Says New Global Physician Leader](#)

6th October 2023

Gender equality in healthcare is not just a goal, but a necessity. It is integral to ensuring the health and well-being of all individuals, leaving no one behind, the newly elected President of the Association said today.

Dr. Lujain AlQodmani, former International Relations Director of the Kuwait Medical Association in her inaugural speech at WMA's General Assembly in Kigali highlighted the glaring gender disparities that persist in healthcare worldwide.

She pointed to the shocking imbalance in COVID-19 vaccinations, where some countries saw only one woman vaccinated for every three men. The President stressed that this disparity extends beyond vaccinations to maternal healthcare, underscoring that not all women have access to the quality care she was privileged to receive...

World Organisation for Animal Health [to 07 Oct 2023]

<https://www.oie.int/en/>

Press Releases, Statements

Quadripartite launches the Working Group on Youth Engagement for Antimicrobial Resistance

5 October 2023

The Quadripartite (Food and Agriculture Organization of the United Nations, United Nations Environment Programme, World Health Organization and World Organisation for Animal Health) announces the creation of a new Working Group on Youth Engagement for Antimicrobial Resistance (AMR). The members of the working group will inform and guide the quadripartite efforts to raise awareness and include young people in global AMR action...

...Over 200 stakeholders participated at the global consultations on AMR awareness raising, organized in 2022 and identified young people (children, students and youth) as a priority audience for awareness and education efforts. Youth play a significant role as future professionals and consumers. They can also be 'agents of change' with their energy and potential influence on national and global decision-making processes. Therefore, the quadripartite organizations have prioritized young people in AMR awareness-raising efforts. The call for expressions of interest to join the working group was published in May 2023, and the response was overwhelming. The 14 members were selected based on their backgrounds, actively considering the need for sectoral, gender and geographical representation...

.....

ARM [Alliance for Regenerative Medicine] [to 07 Oct 2023]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 07 Oct 2023]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 07 Oct 2023]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 07 Oct 2023]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 07 Oct 2023]

<https://ifpma.org/>

Selected Press Releases/Statements

Press release 5 Oct 2023

[Four innovators awarded Africa Young Innovators for Health Award for contributions to Universal Health Coverage](#)

Statement 2 October 2023

[Fifth meeting of the Working Group on Amendments to the International Health Regulations \(2005\)](#)

By IFPMA

On 2 October, IFPMA delivered a statement at the fifth meeting of the Working Group on Amendments to the International Health Regulations (WGIHR) (2005) in Geneva.

...As negotiations take on a more technical deep dive, the industry urges the WGIHR to consider the following two key elements:

- Facilitating and promoting the sharing of outbreak information, including the immediate and unhindered access to pathogens and their genetic information, must be strengthened to support the technical objectives of the IHR; and
- Finding fit-for-purpose outcomes for equitable access to medical countermeasures must not undermine the innovation system, which developed, scaled, and delivered the vaccines, treatments, and tests at record speed during COVID-19. We also call for more inclusive, broader multi-stakeholder dialogue.

International Alliance of Patients' Organizations – IAPO [to 07 Oct 2023]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest announcements identified

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified

PhRMA [to 07 Oct 2023]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

[**AstraZeneca research reveals unique associations between rare changes in genes and plasma proteins that could improve drug discovery with data from over 50,000 UK Biobank participants**](#)

04 October 2023

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - Website not responding at inquiry

Biological E

News - No new digest announcements identified

BioNTech

Press Releases

2 October 2023

[**Statement on Katalin Karikó and Drew Weissman awarded the Nobel Prize in Medicine 2023**](#)

Boehringer

Press Releases

[**Boehringer Ingelheim Partners with Precision Health Research, Singapore to Bring Future Medical Breakthroughs to Patients**](#)

Ingelheim, Germany and Singapore, 2 October 2023 – Boehringer Ingelheim joins forces with Precision Health Research, Singapore (PRECISE) in a new partnership with the joint aim of transforming healthcare and improving patient outcomes in Singapore and beyond.

This partnership will energize Singapore's precision medicine research, innovation and industry collaboration in data science. It will also strengthen Boehringer Ingelheim's data science, enabling the company to connect genetic data with symptoms and lifestyle data in its key research and development (R&D) focus areas. By addressing the diversity gap for Asian genomes, it will also advance both partner's joint ambition to build a database including all ethnicities, enabling the development of treatments for all people worldwide...

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified

Cinnagen

Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media

05 October 2023

[GSK survey finds parents know less about meningitis compared to some other childhood diseases](#)

New multi-country survey finds 93% of parents couldn't identify all three of the most common meningitis symptoms.

IMBCAMS, China

Home - Website not responding at inquiry

Janssen/JNJ

Press Releases

Oct 03, 2023

United States

[Janssen Enters into Agreement with Sanofi to Advance Potential First-In-Class Vaccine Program](#)

Vaccine candidate is being evaluated in Phase 3 study for the prevention of invasive E. coli disease (IED) which affects nearly 10 million adults annually¹

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

10/04/2023

[Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19](#)

Nanogen

News - No new digest announcements identified

Novartis

News

Oct 04, 2023

[Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company](#)

Novavax

Press Releases

Oct 3, 2023

COVID-19

[Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.](#)

Oct 2, 2023

Statement Malaria

R21/Matrix-M™ Malaria Vaccine with Novavax's Adjuvant Technology Receives WHO Recommendation

Pfizer

Recent Press Releases

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

October 05, 2023

Presentations showcase diversity and momentum of Pfizer's growing portfolio of vaccines and anti-infectives

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases

October 3, 2023

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Serum Institute of India

NEWS & ANNOUNCEMENTS

Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out

The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax's adjuvant is critical to reducing over half a million malaria-related deaths annually.

- Oct 2, 2023
R21 Vaccinations at Tanzania clinical site - Photo Credit Tom Wilkinson, University of Oxford
- R21/Matrix-M™ malaria vaccine has been recommended for use by the World Health Organization's Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG)
- Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax's adjuvant technology, R21/Matrix-M™ malaria vaccine demonstrates high efficacy with a reassuring safety profile
- The R21/Matrix-M™ malaria vaccine is an easily deployable vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to countries which are suffering a significant malaria burden
- The Serum Institute of India has already established production capacity for 100 million doses per annum, which will be doubled over the next two years
- The World Health Organization's recommendation today is required for UNICEF to procure and GAVI to purchase the vaccine, paving the way for vaccination of children in populations most at risk
- R21/Matrix-M™ malaria vaccine marks the culmination of 30 years of malaria vaccine research at the University of Oxford's Jenner Institute

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function not operating]

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

[Press Releases](#) - No new digest announcements identified

Takeda

[Newsroom](#)

[Takeda's Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years](#)

October 3, 2023

- Experts Reviewed Data from QDENGAs Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 Participants
- WHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of QDENGAs in Public Vaccination Programs in the Coming Months
- Dengue Poses a Significant and Growing Public Health Burden to People Living in and Traveling to Endemic Countries

Valneva

[Press Releases](#) - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

[Home](#) - Website not responding [404 error]

WestVac Biopharma

[Media](#) - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....
.....

[Contents](#) [[click to move among sections](#)]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

[Journal Watch](#)

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 14, 2023 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 25, Number 10: E719-790

<https://journalofethics.ama-assn.org/issue/geriatric-psychiatry>

Geriatric Psychiatry

Twenty percent of the US population is expected to be 65 years of age or older by 2030. Ageism's pervasiveness in US culture means it is also pervasive in health care and a cause of inequity that profoundly undermines older adults' quality of life. Independence and autonomy losses tend to accompany aging for all of us. Older adults are vulnerable to exploitation and are exposed to late-life stressors that affect their mental health, accompany compromise or loss of independence and autonomy, and tend to track declines in general health and cognitive function. This theme issue investigates reasons why diminishing numbers of geriatric mental health clinicians should draw clinical, ethical, and legal attention to whether and how well US health care and its workforce is prepared to deliver the volume and quality of care older adults deserve.

American Journal of Human Genetics

Oct 05, 2023 Volume 110 Issue 10 p1607-1826

<https://www.cell.com/ajhg/current>

Commentary

[The need for an intersectionality framework in precision medicine research](#)

Maya Sabatello, et al.

Summary

Precision medicine research has seen growing efforts to increase participation of communities that have been historically underrepresented in biomedical research. Marginalized racial and ethnic communities have received particular attention, toward the goal of improving the generalizability of scientific knowledge and promoting health equity. Against this backdrop, research has highlighted three key issues that could impede the promise of precision medicine research: issues surrounding (dis)trust and representation, challenges in translational efforts to improve health outcomes, and the need for responsive community engagement. Existing efforts to address these challenges have predominantly centered on single-dimensional demographic criteria such as race, ethnicity, or sex, while overlooking how these and additional variables, such as disability, gender identity, and socioeconomic factors, can confound and jointly impact research participation. We argue that increasing cohort diversity and the responsiveness of precision medicine research studies to community needs requires an approach that transcends conventional boundaries and embraces a more nuanced, multi-layered, and intersectional framework for data collection, analyses, and implementation. We draw attention to gaps in existing work, highlight how overlapping layers of marginalization might shape and substantiate one another and affect the precision-medicine research cycle, and put forth strategies to facilitate equitable advantages from precision-medicine research to diverse participants and internally heterogeneous communities.

American Journal of Infection Control

September 2023 Volume 51 Issue 9 p967-1082

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

September 2023 Volume 65 Issue 3 p347-550

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

September 2023 113(9)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 109 (2023): Issue 3 (Sep 2023)

<https://www.ajtmh.org/view/journals/tpmd/109/2/tpmd.109.issue-3.xml>

[Reviewed earlier]

Annals of Internal Medicine

September 2023 Volume 176, Issue 9

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 322 September 2023

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/322/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 07 Oct 2023)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 07 Oct 2023)

[Cost minimization analysis of a hexavalent vaccine in Argentina](#)

Argentina currently uses a pentavalent vaccine containing diphtheria, tetanus, pertussis (whole cell), Haemophilus influenza type b and hepatitis B antigens, administered concomitantly with the inactivated polio ...

Authors: Ignacio Olivera, Carlos Grau Pérez, Luis Lazarov, Eduardo Lopez, Cristian Oddo and Hugo Dibarboure

Citation: BMC Health Services Research 2023 23:1067

Content type: Research Published on: 6 October 2023

[Investigating the tendency to use COVID-19 vaccine booster dose in Iran](#)

Vaccine hesitancy is recognized as a significant public health threats, characterized by delays, refusals, or reluctance to accept vaccinations despite their availability. This study, aimed to investigate the ...

Authors: Mehrdad Askarian, AmirAli Rastegar Kazerooni, zahra Shayan, Parisa Karimzadeh, Mohammad Movahedi and Nahid Hatam

Citation: BMC Health Services Research 2023 23:1051

Content type: Research Published on: 2 October 2023

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 07 Oct 2023)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 07 Oct 2023)

[Public attitudes towards genomic data sharing: results from a provincial online survey in Canada](#)

While genomic data sharing can facilitate important health research and discovery benefits, these must be balanced against potential privacy risks and harms to individuals. Understanding public attitudes and p...

Authors: Holly Etchegary, Georgia Darmonkov, Charlene Simmonds, Daryl Pullman and Proton Rahman

Citation: BMC Medical Ethics 2023 24:81

Content type: Research Published on: 7 October 2023

BMC Medicine

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 07 Oct 2023)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 07 Oct 2023)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 07 Oct 2023)

[No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 07 Oct 2023)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2023 - Volume 28 - 5

<https://ebm.bmj.com/content/28/5>

[New issue; No digest content identified]

BMJ Global Health

August 2023 - Volume 8 - 9

<https://gh.bmj.com/content/8/9>

[Reviewed earlier]

Bulletin of the Atomic Scientists

September 2023

<https://thebulletin.org/magazine/2023-09/>

Contents

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 101(10); 2023 Oct 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/446112/>

Editorials

[Establishing the impact of WHO's normative and standard-setting functions: a call for papers](#)

Lisa M Askie, Rebekah AL Thomas, Rok Ho Kim, Mubashar Sheikh, Jeremy Farrar

Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

doi: 10.2471/BLT.23.290829

PMCID: PMC10523809

[What's needed to sustain malaria elimination in the Region of the Americas](#)

Maria Eugenia Grillet

Bull World Health Organ. 2023 Oct 1; 101(10): 619–619A. Published online 2023 Oct 1.

doi: 10.2471/BLT.23.290506

PMCID: PMC10523816

Systematic Reviews

[Elimination and eradication goals for communicable diseases: a systematic review](#)

Laila Khawar, Basil Donovan, Rosanna W Peeling, Rebecca J Guy, Skye McGregor

Bull World Health Organ. 2023 Oct 1; 101(10): 649–665. Published online 2023 Sep 6.

doi: 10.2471/BLT.23.289676

PMCID: PMC10523812

Abstract

Objective

To consolidate recent information on elimination and eradication goals for infectious diseases and clarify the definitions and associated terminology for different goals.

Methods

We conducted a systematic search of the World Health Organization's Institutional Repository for Information Sharing (WHO IRIS) and a customized systematic Google advanced search for

documents published between 2008 and 2022 on elimination or eradication strategies for infectious conditions authored by WHO or other leading health organizations. We extracted information on names of infectious conditions, the elimination and eradication goals and timelines, definitions of goals, non-standardized terminology, targets and assessment processes.

Findings

We identified nine goals for 27 infectious conditions, ranging from disease control to eradication. In comparison with the hierarchy of disease control, as defined at the Dahlem Workshop in 1997, six goals related to disease control with varying levels of advancement, two related to elimination and one to eradication. Goals progressed along a disease-control continuum, such as end of disease epidemic to pre-elimination to elimination as a public health problem or threat. We identified the use of non-standardized terminology with certain goals, including virtual elimination, elimination of disease epidemics, public health threat and public health concern.

Conclusion

As we approach the 2030 target date to achieve many of the goals related to disease control and for other infections to become candidates for elimination in the future, clarity of definitions and objectives is important for public health professionals and policy-makers to avoid misperceptions and miscommunication.

Policy & Practice

[Differentiating sex and gender in health research to achieve gender equity](#)

Michelle R Kaufman, Evan L Eschliman, Tahilin Sanchez Karver
Bull World Health Organ. 2023 Oct 1; 101(10): 666–671. Published online 2023 Aug 17.
doi: 10.2471/BLT.22.289310
PMCID: PMC10523819

[Lessons from a global antimicrobial resistance surveillance network](#)

Etienne Ruppé, on behalf of the Network for Enhancing Tricycle ESBL Surveillance Efficiency (NETESE) group
Bull World Health Organ. 2023 Oct 1; 101(10): 672–678. Published online 2023 Sep 6.
doi: 10.2471/BLT.22.289520
PMCID: PMC10523813

Cell

Sep 28, 2023 Volume 186 Issue 20 p4257-4474
<https://www.cell.com/cell/current>
[Reviewed earlier]

Child Care, Health and Development

Volume 49, Issue 5 Pages: 787-940 September 2023
<https://onlinelibrary.wiley.com/toc/13652214/current>

SPECIAL ISSUE: THE PERVASIVE EFFECTS OF COVID-19 ON CHILDREN: A GLOBAL PERSPECTIVE PART II

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 114, Issue 4 Pages: 723-932 October 2023
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>
White Paper Open Access

Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval—An Industry Perspective

Rui Zhu, et al. International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Real-World Data Working Group
Pages: 751-767
First Published: 02 July 2023

Reviews

A Case for Synthetic Data in Regulatory Decision-Making in Europe

Clara Alloza, Bethany Knox, Hanaya Raad, Mireia Aguilà, Ciara Coakley, Zuzana Mohrova, Élodie Boin, Marc Bénard, Jessica Davies, Emmanuelle Jacquot, Coralie Lecomte, Alban Fabre, Michael Batech
Pages: 795-801
First Published: 13 July 2023

Design and Execution of Sustainable Decentralized Clinical Trials

Pritibha Singh, Andrea M. Burden, Fanni Natanegara, Robert A. Beckman
Pages: 802-809
First Published: 25 July 2023

Clinical Therapeutics

September 2023 Volume 45 Issue 9 p807-924
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 20 Issue 5, October 2023
<https://journals.sagepub.com/toc/ctja/20/5>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 07 Oct 2023]
[No new digest content identified]

Contemporary Clinical Trials

Volume 132 September 2023
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/132/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 6, Issue 4 / August 2023
<https://www.liebertpub.com/toc/crispr/6/4>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 10, issue 3, September 2022

<https://link.springer.com/journal/40142/volumes-and-issues/10-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 39, Issue 9 2023

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2023 - Volume 36 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 07 Oct 2023]

[No new digest content identified]

Developing World Bioethics

Volume 23, Issue 3 Pages: 197-292 September 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 33, Issue 7, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 41, Issue 5 September 2023

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 16 - Issue 6 - December 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 47, Issue 3 Pages: 543-846 July 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/3>

[Reviewed earlier]

EMBO Reports

Volume 24 Issue 9 6 September 2023

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 29, Number 10—October 2023

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 44 September 2023

<https://www.sciencedirect.com/journal/epidemics/vol/44/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 151 - 2023

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 45, Issue 5 Pages: 1-47 September–October 2023

<https://onlinelibrary.wiley.com/toc/25782363/current>

Adaptive clinical trials :: Deprioritizing ongoing clinical trials

Articles

[Ethics of Adaptive Designs for Randomized Controlled Trials](#)

Gershon Chongwe, Joseph Ali, Dan Kabonge Kaye, Charles Michelo, Nancy E. Kass

Pages: 2-14

First Published: 01 October 2023

[Deprioritization of Ongoing Clinical Trials](#)

Barbara E. Bierer, Deborah A. Zarin, Luke Gelinias

Pages: 27-33

First Published: 01 October 2023

Ethics & International Affairs

Volume 37 - Issue 2 - Summer 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 30 October 2023

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/30/suppl/C>

[New issue; No digest content identified]

The European Journal of Public Health

Volume 33, Issue 4, August 2023

<https://academic.oup.com/eurpub/issue/33/4>

[Reviewed earlier]

Expert Review of Vaccines

Vol 22 (1) 2023 *Issue In Progress*

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

September/October 2023 Volume 102, Number 5

<https://www.foreignaffairs.com/issues/2023/102/5>

[Reviewed earlier]

Forum for Development Studies

Volume 50, 2023 - Issue 3

[New issue; No digest content identified]

Genetics in Medicines

Volume 25, Issue 9 September 2023

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/9>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 07 Oct 2023]

[No new digest content identified]

Global Health Action

Volume 16, Issue 1 (2023)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 11, No. 4 August 28, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 07 Oct 2023]

[No new digest content identified]

Global Public Health

Volume 18, Issue 1 (2023)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 07 Oct 2023]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 1, June 2023,

<https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/>

Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks

...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

Health Economics, Policy and Law

Volume 18 - Issue 3 - July 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 38, Issue 8, October 2023

<https://academic.oup.com/heapol/issue/38/8>

ORIGINAL ARTICLES

[Contributions of declining mortality, overall and from HIV, TB and malaria, to reduced health inequality and inequity across countries](#)

Markus Haacker

Health Policy and Planning, Volume 38, Issue 8, October 2023, Pages 939–948,

<https://doi.org/10.1093/heapol/czad046>

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 07 Oct 2023]

[No new digest content identified]

Human Gene Therapy

Volume 34, Issue 17-18 / September 2023

<https://www.liebertpub.com/toc/hum/34/17-18>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 18, Issue 5, 2022

<https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList>

[Reviewed earlier]

Immunity

Sep 12, 2023 Volume 56 Issue 9 p1975-2176

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 07 Oct 2023]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 07 Oct 2023]

[Factors associated with recommendation behaviors of four non-National Immunization Program vaccines: a cross-sectional survey among public health workers in China](#)

Immunization is a crucial preventive measure to safeguard children under five years old against a range of diseases. In China, the coverage rate of non-National Immunization Program (non-NIP) vaccines can be i...

Authors: Yun Lyu, Xiaozhen Lai, Yidi Ma and Hai Fang

Citation: Infectious Diseases of Poverty 2023 12:91

Content type: Research Article Published on: 7 October 2023

International Health

Volume 15, Issue 5, September 2023

<https://academic.oup.com/inthealth/issue/15/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 1 (Jul 2023)

<https://brill.com/view/journals/hrlr/12/1/hrlr.12.issue-1.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 10 No. 9 (2023): September 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/104>

[Reviewed earlier]

International Journal of Epidemiology

Volume 52, Issue 4, August 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

Table of contents

[Reviewed earlier]

JAMA

October 3, 2023, Vol 330, No. 13, Pages 1209-1295

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years](#)

Sara Y. Tartof, PhD, MPH; Timothy B. Frankland, MA; Jeff M. Slezak, MS; et al.

free access

JAMA. 2023;330(13):1282-1284. doi:10.1001/jama.2023.17473

This study examines the association of the receipt of wild-type BNT162b2 vaccine with medically attended COVID-19 outcomes among children younger than 5 years in the US.

Editorial

[Peer Review and Scientific Publication at a CrossroadsCall for Research for the 10th International Congress on Peer Review and Scientific Publication](#)

John P. A. Ioannidis, MD, DSc; Michael Berkwits, MD, MSCE; Annette Flanagin, RN, MA; et al.

free access

JAMA. 2023;330(13):1232-1235. doi:10.1001/jama.2023.17607

Editorial

[Three Decades of Peer Review Congresses](#)

Drummond Rennie, MD; Annette Flanagin, RN, MA

JAMA

JAMA Health Forum

September 2023, Vol 4, No. 9

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

September 2023, Vol 177, No. 9, Pages 877-985

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

September 2023 - Volume 21 - Issue 9

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

September 2023 Volume 73 Issue 3 p401-610

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 77 (2023)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 5, October 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-5>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

June 18, 2023 Vol 6, No 06 (2023)

<https://www.cmro.in/index.php/jcmro/issue/view/68>

[Reviewed earlier]

Journal of Development Economics

Volume 164 September 2023

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/164/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 4, October 2023

<http://journals.sagepub.com/toc/jre/current>

Ethical Issues in Research in Low and Middle-Income Countries

[Reviewed earlier]

Journal of Epidemiology & Community Health

September 2023 - Volume 77 - 9

<https://jech.bmj.com/content/77/9>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 16, Issue 3 Pages: 259-413 September 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

ARTICLES

[New issue; No digest content identified]

Journal of Global Ethics

Volume 19, Issue 2 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 3, August 2023

<https://muse.jhu.edu/issue/50808>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 5, October 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-5>

Contents

[New issue; No digest content identified]

Journal of Immigrant & Refugee Studies

Volume 21, 2023 _ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 228, Issue 5, 1 September 2023

<https://academic.oup.com/jid/issue/228/5>

[Reviewed earlier]

Journal of International Development

Volume 35, Issue 6 Pages: 961-1548 August 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

October 2023 - Volume 49 - 10

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 3 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

The Journal of Pediatrics

Volume 261, October 2023

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/261/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 07 Oct 2023]

[No new digest content identified]

Journal of Public Health Management & Practice

September/October 2023 - Volume 29 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 44, issue 3, September 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-3>

[Reviewed earlier]

Journal of the Royal Society – Interface

October 2023 Volume 20 Issue 207

<https://royalsocietypublishing.org/toc/rsif/current>

[No new digest content identified]

Journal of Travel Medicine

Volume 30, Issue 5, July 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 97 Number 9 September 2023

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

The Lancet

Oct 07, 2023 Volume 402 Number 10409 p1199-1298

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

To mark our bicentennial year, we have published a special issue to celebrate, self-reflect and amplify our founding ideas with our present-day impact and vision for the future. Discover more of our Lancet 200 campaign and the five health issues we're spotlighting this year



Editorial

[The Lancet's 200 years: much more to do](#)

The Lancet

Oct 5, 2023, is The Lancet's 200th anniversary. To mark the moment, we are this week publishing a special theme issue to reflect on what our history means and what the future might hold. The Lancet's founder, Thomas Wakley, intended to open medical knowledge to a wider readership and to engage politically with the health issues of his time. In their review article, Martin Gorsky and Agnes Arnold-Forster describe The Lancet's participation in some of the biggest scientific discoveries of the past two centuries, together with the campaigns our predecessors initiated or joined. But the reality is that the personality of the journal—its interests and attitudes—has evolved with each new generation of editors, reviewers, authors, and contributors.

The journal's perspective today is very different from that of 1823. Our collective task is to reinvent Wakley's purpose for a new time. Perhaps the most important difference between then and now is that we seek to be more inclusive of communities worldwide. Our intention is to foster a truly global conversation about health, medicine, and medical science, with the goals of advancing health, health equity, and social justice. To achieve these aims, we depend on collaborations with the medical community, especially the academic medical community—indeed, we view the research community as a transformative untapped resource in society for science-based advocacy and social change.

To try to accelerate progress towards our objectives and to mark our special anniversary, we have chosen five areas that we see as important priorities (Spotlights): **universal health coverage (UHC), mental health, climate change and health, research for health, and child and adolescent health. What have we learned so far? For UHC, despite fine words and false promises from political leaders and international agencies, lack of sustainable financing, fragmentation of services, and siloed approaches are continuing barriers to progress. Midway through the Sustainable Development Goals, UHC needs not merely renewed attention, but also concrete operational commitments at national levels. The prospects are not encouraging...**

...200 years isn't a milestone. It is only a brief moment in the long and erratic history of human endeavour. Much of what we call progress in health is as much due to increasing prosperity and wider educational opportunity, as it is to technical medical advance. But the importance of health as an idea in society lies beyond the immediate materiality of bodily wellbeing. Our concern for health and our investment in health systems are proof of our social commitments to one another—health is an expression of our human solidarity. We will be learning lessons from our anniversary Spotlights, lessons that we will take with us into 2024 and beyond. Meanwhile, we wish to thank you for being part of a community inspired by the notion that practising medicine is a privilege that comes with a great responsibility—to advance the health of society, as well as the individual person.

Articles

[Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa \(INTE-AFRICA\): a pragmatic cluster-randomised, controlled trial](#)

Sokoine Kivuyo, et al. on behalf of the RESPOND-AFRICA Group

Open Access

Review

[The Lancet 1823–2023: the best science for better lives](#)

Martin Gorsky, Agnes Arnold-Forster

Summary

The Lancet celebrates its 200th anniversary in 2023. In this survey of the journal's history, we explore how it has contributed to shaping medicine both in the UK and internationally, and how it has demonstrated a commitment to "The best science for better lives". For two centuries, the journal has published pioneering articles on key developments in medical science and the organisation of health care. We explore the campaigning and advocacy work of the journal through several indicative areas where science and policy meet, balancing national and global themes over the 19th and 20th centuries. Themes include the raising of professional standards; environmental health in urbanising Britain; the transformation of surgery; the emergence of tropical medicine; the science and politics of vaccination; the advance towards universal health coverage; and the transition from international to global health. In the imperial era, both the journal's research reports and editorial stance were sometimes inflected with colonial attitudes, although it consistently presented medicine as an international endeavour. The Lancet's blend of science and advocacy demonstrates a track record of campaigning for medicine in the cause of social betterment.

The Lancet Child & Adolescent Health

Sep 2023 Volume 7 Number 9 p599-670, e17

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Sep 2023 Volume 5 Number 9e 545-e631

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Sep 2023 Volume 11 Number 9 e1314-e1474

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Sep 2023 Volume 23 Number 9 p983-1094, e326-e389

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Sep 2023 Volume 8 Number 9 e659-e742

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Sep 2023 Volume 11 Number 9 p755-850, e78-e83

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 27, issue 9, September 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-9>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 43 Issue 6, August 2023

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Oct 04, 2023 Volume 31 Issue 10 p2813-3104

<https://www.cell.com/molecular-therapy/current>

[New issue; No digest content identified]

Nature

Volume 622 Issue 7981, 5 October 2023

<https://www.nature.com/nature/volumes/621/issues/7981>

Perspective 04 Oct 2023

[The status of the human gene catalogue](#)

Paulo Amaral, Silvia Carbonell-Sala, Steven L. Salzberg

Abstract

Scientists have been trying to identify every gene in the human genome since the initial draft was published in 2001. In the years since, much progress has been made in identifying protein-coding genes, currently estimated to number fewer than 20,000, with an ever-expanding number of distinct protein-coding isoforms. Here we review the status of the human gene catalogue and the efforts to complete it in recent years. Beside the ongoing annotation of protein-coding genes, their isoforms and pseudogenes, the invention of high-throughput RNA sequencing and other technological breakthroughs have led to a rapid growth in the number of reported non-coding RNA genes. For most of these non-coding RNAs, the functional relevance is currently unclear; we look at recent advances that offer paths forward to identifying their functions and towards eventually completing the human gene catalogue. Finally, we examine the need for a universal annotation standard that includes all medically significant genes and maintains their relationships with different reference genomes for the use of the human gene catalogue in clinical settings.

Nature Biotechnology

Volume 41 Issue 9, September 2023

<https://www.nature.com/nbt/volumes/41/issues/9>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 07 Oct 2023)

[No new digest content identified]

Nature Genetics

Volume 55 Issue 9, September 2023

<https://www.nature.com/ng/volumes/55/issues/9>

[Reviewed earlier]

Nature Human Behaviour

Volume 7 Issue 9, September 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/9>

[Reviewed earlier]

Nature Medicine

Volume 29 Issue 9, September 2023

<https://www.nature.com/nm/volumes/29/issues/9>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 22 Issue 9, September 2023

<https://www.nature.com/nrd/volumes/22/issues/9>

[Reviewed earlier]

Nature Reviews Genetics

Volume 24 Issue 9, September 2023

<https://www.nature.com/nrg/volumes/24/issues/9>

[Reviewed earlier]

Nature Reviews Immunology

Volume 23 Issue 9, September 2023

<https://www.nature.com/nri/volumes/23/issues/9>

[Reviewed earlier]

New England Journal of Medicine

October 5, 2023 Vol. 389 No. 14

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 07 Oct 2023]

[No new digest content identified]

Pediatrics

Volume 152, Issue 4 October 2023

<https://publications.aap.org/pediatrics/issue/152/4>

Articles

[Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety](#)

Jaime Restrepo, MD; Teobaldo Herrera, MD; Rudiwilai Samakoses, MD; Julio C. Reina, MD; Punnee Pitisuttithum, MBBS, DTM&H ...

The 9vHPV vaccine demonstrated sustained immunogenicity and effectiveness through ~10 years post 3 doses of 9vHPV vaccination of boys and girls aged 9 to 15 years.

Quality Reports

[Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease](#)

Adam P. Yan, MD; Natasha M. Archer, MD, MPH; Dianne Arnold, RN, MSN; Eileen Hansbury, PA-C, MS; Matthew M. Heeney, MD ...

The COVID-19 vaccine is important for children with sickle cell disease (SCD). This quality improvement project's objective was to increase the proportion of children with SCD receiving ≥ 2 COVID-19 vaccine doses to $\geq 70\%$ by June 2022.

PharmacoEconomics

Volume 41, issue 10, October 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-10>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 07 Oct 2023)

[A call to implement preclinical study registration in animal ethics review](#)

Matthew S. Jeffers, Aileen MacLellan, Marc T. Avey, Julia ML Menon, Janet Sunohara-Neilson, Dean A. Fergusson, Manoj M. Lalu

Perspective | published 05 Oct 2023 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3002293>

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 07 Oct 2023)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 07 Oct 2023)

[Internal and external factors affecting vaccination coverage: Modeling the interactions between vaccine hesitancy, accessibility, and mandates](#)

Kerri-Ann M. Anderson, Nicole Creanza

Research Article | published 04 Oct 2023 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0001186>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 07 Oct 2023)

[Prioritizing persons deprived of liberty in global guidelines for tuberculosis preventive treatment](#)

Aditya Narayan, Argita D. Salindri, Salmaan Keshavjee, Monde Muyoyeta, Kavindhran Velen, Zulma V. Rueda, Julio Croda, Salome Charalambous, Alberto L. García-Basteiro, Sheela V. Shenoi, Christinne C. M. Gonçalves, Liliane Ferreira da Silva, Lia G. Possuelo, Sarita Aguirre, Gladys Estigarribia, Guillermo Sequera, Louis Grandjean, Lily Telisinghe, Michael E. Herce, Fernanda Dockhorn, Frederick L. Altice, Jason R. Andrews

Policy Forum | published 03 Oct 2023 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004288>

Summary points

- Persons deprived of liberty (PDLs) are disproportionately impacted by tuberculosis, with high incidence rates and often limited access to diagnostics, treatment, and preventive measures.
- The World Health Organization (WHO) expanded its recommendations for tuberculosis preventive treatment (TPT) to many high-risk populations, but their guidance does not include PDL, and most low- and middle-income countries do not routinely provide TPT in prisons.
- Recent studies demonstrate high acceptability and completion rates of short-course TPT regimens in jails and prisons; costs of these regimens have been markedly reduced through international agreements, making this an opportune for further expanding their use.

- We argue that PDL should be a priority group for TPT in national guidelines and discuss implementation considerations and resource needs for TPT programs in carceral facilities.
- Scaling access to TPT for PDL is important for reducing disease and transmission in this population; it is also critical to advancing an equitable response to tuberculosis.

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 07 Oct 2023)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 07 Oct 2023]

[Preferences for public engagement in decision-making regarding four COVID-19 non-pharmaceutical interventions in the Netherlands: A survey study](#)

Sophie Kemper, Marloes Bongers, Frank Kupper, Marion De Vries, Aura Timen

Research Article | published 05 Oct 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0292119>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 07 Oct 2023]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

October 3, 2023 vol. 120 no. 40

<https://www.pnas.org/toc/pnas/120/40>

[New issue; No digest content identified]

PNAS Nexus

Volume 2, Issue 9, September 2023

<https://academic.oup.com/pnasnexus/issue/2/9>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 38 - Issue 5 - October 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 174 September 2023

<https://www.sciencedirect.com/journal/preventive-medicine/vol/174/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

11 October 2023 Volume 290 Issue 2008

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 222 Pages e1-e26, 1-230 (September 2023)

<https://www.sciencedirect.com/journal/public-health/vol/222/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 2, July 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

Public Health Reports

Volume 138 Issue 5, September/October 2023

<https://journals.sagepub.com/toc/phrg/138/5>

[Reviewed earlier]

Qualitative Health Research

Volume 33 Issue 11, September 2023

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 19 Issue 3, July 2023

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 07 Oct 2023]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 43, Issue 10 Pages: 1917-2146 October 2023

<https://onlinelibrary.wiley.com/toc/15396924/current>

ORIGINAL ARTICLES

[Governmental anti-pandemic policies, vaccination, population mobility, Twitter narratives, and the spread of COVID-19: Evidence from the European Union countries](#)

Elena Fedorova, Svetlana Ledyeva, Oksana Kulikova, Alexandr Nevredinov

Pages: 1975-2003

First Published: 09 January 2023

[The benefits and costs of U.S. employer COVID-19 vaccine mandates](#)

Maddalena Ferranna, Lisa A. Robinson, Daniel Cadarette, Michael R. Eber, David E. Bloom

Pages: 2053-2068

First Published: 17 January 2023

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 07 Oct 2023]

[Reviewed earlier]

Science

Volume 382| Issue 6666| 6 Oct 2023

<https://www.science.org/toc/science/current>

Special issue: Ancient DNA

Introduction to Special Issue

[Glimpses of genomes past](#)

BY Corinne Simonti, Madeleine Seale

05 Oct 2023: 46-47

Ancient DNA has radically altered our understanding of the evolutionary history of many plants and animals, as well as our own. It has revealed areas of our genomes that were inherited from closely related archaic hominins, granted insight into past ecosystems, and unveiled extinct species and populations from across the tree of life. Each sample of ancient DNA is a snapshot of a place and time, giving a brief glimpse into the past. A better understanding of the DNA that was inherited by modern individuals—and, sometimes more importantly, the DNA that wasn't—can inform us about many evolutionary processes, including adaptation, speciation, and domestication.

As the field of ancient DNA matures, we now have the foundational understanding to appreciate the finer details granted by these snapshots. Studies of past plants and animals can help to illuminate the changing ecological landscape, as well as our role in those changes. When human studies are done ethically and responsibly, we can integrate with communities and rediscover stories that have been lost or erased from history, thereby possibly reconnecting modern people to historical relatives. Beyond these focused investigations, however, the technical limits of ancient DNA remain unclear. Although methodologies for capturing ancient DNA have greatly improved, how long DNA can survive environmental damage in different climates and conditions is still an open question. Though we will never be able to get a full picture of the past, studies of ancient DNA continue to reveal previously unknown aspects of history across organisms. This special issue examines the changing landscape of how ancient DNA is studied today, including previously untapped sources,

improvements in technology, and ethical challenges, and what we've learned about ourselves through ancient DNA.

Science and Engineering Ethics

Volume 29, issue 5, October 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-5>

[Reviewed earlier]

Science Translational Medicine

Volume 15| Issue 716| 4 Oct 2023

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 07 Oct 2023]

[No new digest content identified]

Social Science & Medicine

Volume 332 September 2023

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/332/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 07 Oct 2023]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 44, issue 4, August 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-4>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 54 July–August 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/54/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 28, Issue 10 Pages: i-iv, 797-838 October 2023

<https://onlinelibrary.wiley.com/toc/13653156/current>

RESEARCH ARTICLE

EDITORS' CHOICE

Open Access

[Antimalarial drug efficacy and resistance in malaria-endemic countries in HANMAT-PIAM net countries of the Eastern Mediterranean Region 2016–2020: Clinical and genetic studies](#)

Mariam Adam, et al.

Pages: 817-829

First Published: 13 September 2023

Vaccine

Volume 41, Issue 43 Pages 6403-6542 (13 October 2023)

<https://www.sciencedirect.com/journal/vaccine/vol/41/issue/43>

Short communication Open access

[Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries](#)

Ishani Mathur, Rachael Church, Anika Ruisch, Karina Noyes, ... Christian Suharlim

Pages 6406-6410

Abstract

Most countries rolled out COVID-19 vaccination during 2021–2022. However, COVID-19 vaccine delivery cost estimates are still needed to support planning and budgeting to integrate COVID-19 vaccines into routine programs and to target high risk populations, specifically within resource-scarce contexts. Management Sciences for Health and the COVID-19 Vaccine Delivery Partnership Working Group collected country-level data through two surveys exploring global experiences with vaccine roll-out. 40 respondents from 27 countries responded to the surveys in November 2021 and May 2022. Respondents described their country's human resources needs, vaccine delivery modalities, demand generation strategies, booster uptake, cold chain capacity, supplies, and sub-population targets. The surveys highlighted unexpected trends in hiring, reliance on newer and costlier delivery and demand generation methods and significant gaps regarding HR, supplies, boosters, cold chain and reaching sub-populations. These types of opportunity assessments are useful ways of rapidly filling gaps in information needed to adequately cost alternative delivery strategies.

Review article Open access

[Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness](#)

Nicole Shaver, Melanie Katz, Gideon Darko Asamoah, Lori-Ann Linkins, ... Julian Little

Review article Abstract only

[Review: Factors influencing parents' decisions to vaccinate children against COVID-19](#)

Haifa S. Alharbi

Pages 6419-6425

Research article Open access

[Vaccination coverage survey of children aged 1–3 years in Beijing, China, 2005–2021](#)

Wen-yan Ji, Dong-lei Liu, Rui Yu, Liang Miao, ... Jian-Ping Yu

Pages 6444-6452

Research article Abstract only

[Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study](#)

Nusrat Homaira, Wen-Qiang He, Jocelyne McRae, Kristine Macartney, Bette Liu

Pages 6522-6529

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 07 Oct 2023]

Latest Articles [Selected]

Systematic Review

Vaccine Hesitancy of COVID-19 among Parents for Their Children in Middle Eastern Countries—A Systematic Review

by [Muhammad Shahid Iqbal](#)^{1,*}, [Salah-Ud-Din Khan](#)² [Shafqat Qamer](#)³ and [Saeed Vohra](#)

Vaccines 2023, 11(10), 1556; <https://doi.org/10.3390/vaccines11101556>

Received: 13 August 2023 / Revised: 12 September 2023 / Accepted: 21 September 2023 /

Published: 1 October 2023

Abstract

The current systematic review presents COVID-19 vaccine hesitancy among parents for their children in Middle Eastern countries. Moreover, the vaccine acceptance rate of parents from the Middle East and the factors effecting the acceptance rate were reviewed and summarized. For this systematic review, basic electronic academic databases (Scopus, Science Direct, ProQuest, Web of Science and PubMed) were used for the search, along with a manual search on Google Scholar. This systematic review was conducted by following the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)” guidelines. Moreover, utilizing the framework of the PECO-S (Population Exposure Comparison Outcome Study design), various observational studies were recruited for this review. Out of 2123 studies, 25 studies meeting the inclusion criteria were included in the current review. All of the included studies were about parental vaccine hesitancy for COVID-19 in Middle Eastern countries and published during 2020–2022. Overall, 25 research papers comprising 10 different Middle Eastern countries with 33,558 parents were included. The average age of parents was 39.13 (range: 18–70) years, while the mean age of children was 7.95 (range: 0–18) years. The overall hesitancy rate was 44.2% with a SD of ± 19.7 . The included studies presented enhanced COVID-19 vaccine hesitancy among parents in Middle Eastern countries. The lower vaccine acceptance rate among parents was mainly because of a fear of the potential side effects. Furthermore, the lack of information regarding vaccine safety and efficacy, the fear of unreported side effects and concerns about the authenticity of vaccine development and preparation were the predictors of parental COVID-19 vaccine hesitancy among Middle Eastern countries.

Value in Health

October 2023 Volume 26 Issue 10 p1435-1580

<https://www.valueinhealthjournal.com/current>

POLICY PERSPECTIVE

Recognizing the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability, or Willingness?

Margherita Neri, et al.

Published online: July 03, 2023

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 07 Oct 2023]

Selected Research

Research Article metrics AWAITING PEER REVIEW

[How resilient were family planning programs during the COVID-19 pandemic? Evidence from 70 countries](#) [version 1; peer review: awaiting peer review]

Karen Hardee, Rebecca Rosenberg, John Ross, Imelda Zosa-Feranil

Peer Reviewers Invited

Funder - Bill and Melinda Gates Foundation

PUBLISHED 28 Sep 2023

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 07 Oct 2023]

[Filter: All articles]

Selected Research

[Effectiveness of one dose of MVA-BN vaccine against mpox infection in males in Ontario, Canada: A target trial emulation](#)

Christine Navarro, Cindy Lau, Sarah A Buchan, Ann Burchell, Sharifa Nasreen, Lindsay Friedman, Evaezi Okpokoro, Peter Austin, Darrell Tan, Jonathan Gubbay, Jeffrey C Kwong, Sharmistha Mishra
medRxiv 2023.10.04.23296566; doi: <https://doi.org/10.1101/2023.10.04.23296566>

[A mixed method study to assess behavioral and social predictors of parent/caregiver's intention to vaccinate their children against COVID-19 disease in an Indian state marked by significant health disparities.](#)

Tulika Singh, Sanjay Kumar, Setu Sinha, Varsha Singh

medRxiv 2023.10.05.23296592; doi: <https://doi.org/10.1101/2023.10.05.23296592>

[Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa](#)

Tom Sumner, Rebecca A Clark, Christinah Mukandavire, Allison A Portnoy, Chathika Krishan Weerasuriya, Roel Bakker, Danny Scarponi, Mark Hatherill, Nicolas A Menzies, Richard G White
medRxiv 2023.10.04.23296538; doi: <https://doi.org/10.1101/2023.10.04.23296538>

[The TB vaccine clinical trial centre directory: an inventory of clinical trial centres in sub-Saharan Africa](#)

Puck Teetje Pelzer, Marit Holleman, Michelle EH Helinski, Ana Lucia Weinberg, Pauline Beattie, Thomas Nyirenda, Job van Rest, Gerald Voss

medRxiv 2023.10.04.23296539; doi: <https://doi.org/10.1101/2023.10.04.23296539>

[Early underdetected dissemination across countries followed by extensive local transmission propelled the 2022 mpox epidemic](#)

Miguel I. Paredes, Nashwa Ahmed, Marlin Figgins, Vittoria Colizza, Philippe Lemey, John T McCrone, Nicola F Müller, Cécile Tran-Kiem, Trevor Bedford

medRxiv 2023.07.27.23293266; doi: <https://doi.org/10.1101/2023.07.27.23293266> Revision

[Understanding the factors affecting global political priority for controlling sexually transmitted infections: a qualitative policy analysis](#)

Dadong Wu, Nicola Low, Sarah J Hawkes nicola.low@unibe.ch

medRxiv 2023.10.03.23296476; doi: <https://doi.org/10.1101/2023.10.03.23296476>

Abstract

Introduction Sexually transmitted infections (STIs) are a significant public health challenge, but there is a perceived lack of political priority in addressing STIs as a global health issue. Our study aimed to understand the determinants of global political priority for STIs since the 1980s and to discern implications for future prioritisation.

Methods Through semi-structured interviews from July 2021 to February 2022, we engaged 20 key stakeholders (8 women, 12 men) from academia, United Nations agencies, international non-governmental organisations, philanthropic organisations, and national public health agencies. A published policy framework was employed for thematic analysis, and findings triangulated with relevant literature and policy documents. We examined issue characteristics, prevailing ideas, actor power dynamics and political contexts.

Results A contrast in perspectives before and after the year 2000 emerged. STI control was high on the global health agenda during the late 1980s and 1990s, as a means to control HIV. A strong policy community agreed on evidence about the high burden of STIs and that STI management could reduce the incidence of HIV. The level of importance decreased when further research evidence did not find an impact of STI control interventions on HIV incidence. Since 2000, cohesion in the STI community has decreased. New framing for broad STI control has not emerged.

Interventions that have been funded, such as human papillomavirus vaccination and congenital syphilis elimination have been framed as cancer control or improving newborn survival, rather than as STI control.

Conclusion Globally, the perceived decline in STI control priority might stem from discrepancies between investment choices and experts' views on STI priorities. Addressing STIs requires understanding the intertwined nature of politics and empirical evidence in resource allocation. The ascent of universal health coverage presents an opportunity for integrated STI strategies but high-quality care sustainable funding and strategic coordination are essential.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 07 Oct 2023]

Selected Research

Open Letter Open Access

[Multidisciplinary approach to community engagement in global public health research](#)

[version 1; peer review: awaiting peer review]

Oluwafemi Adeagbo, et al. oluwafemi-adeagbo@uiowa.edu

Abstract

Recently, there has been a renewed interest in the role of community engagement in knowledge production and ethical issues such as 'helicopter research', indicating exploitative research activities of some researchers as well as short-term relationships with research communities especially in low- and middle-income countries. This approach is detrimental to both communities and the larger

scientific community as this may breed mistrust. Major institutions such as the National Institute of Health and Care Research in the United Kingdom have highlighted the importance of community engagement as a tool to improve the reach, quality, and impact of the research by incorporating the voices and concerns of marginalized communities. Similarly, in its 2022 guidance, the American Society for Human Genetics (ASGH) highlights the need to address underrepresentation in genomics research through community engagement. Establishing ethical and meaningful long-term relationships can be challenging especially for researchers who are not members of the community or those from other countries. This article describes how 'community-engaged research' can address some ethical challenges in global public health in different cultural settings.

Study Protocol Open Access

[A feasibility study of controlled human infection with intradermal Bacillus Calmette–Guérin \(BCG\) injection: Pilot BCG controlled human infection model](#) [version 1; peer review: awaiting peer review]

Emma Carter *, et al.

Abstract

Tuberculosis (TB) caused 1.5 million deaths in 2020, making it the leading infectious killer after COVID-19. Bacille Calmette-Guerin (BCG) is the only licensed vaccine against TB but has sub-optimal efficacy against pulmonary TB and reduced effectiveness in regions close to the equator with high burden. Efforts to find novel vaccines are hampered due to the need for large-scale, prolonged, and costly clinical trials. Controlled human infection models (CHIMs) for TB may be used to accelerate vaccine development by ensuring only the most promising vaccine candidates are selected for phase 3 trials, but it is not currently possible to give participants *Mycobacterium tuberculosis* as a challenge agent.

study aims to replicate and refine an established BCG CHIM at the Liverpool School of Tropical Medicine. Participants will receive an intradermal injection with licensed BCG vaccine (Statens Serum Institut strain). In phase A, participants will undergo punch biopsy two weeks after administration, paired with minimally invasive methods of skin sampling (skin swab, microbiopsy, skin scrape). BCG detection by classical culture and molecular methods will be compared between these techniques and gold standard punch biopsy. Techniques meeting our pre-defined sensitivity and specificity criteria will be applied in Phase B to longitudinally assess intradermal BCG growth two, seven and fourteen days after administration. We will also measure compartmental immune responses in skin, blood and respiratory mucosa in Phase B.

This feasibility study will transfer and refine an existing and safe model of BCG controlled human infection. Longitudinal BCG quantification has the potential to increase model sensitivity to detect vaccine and therapeutic responses. If successful, we aim to transfer the model to Malawi in future studies, a setting with endemic TB disease, to accelerate development of vaccines and therapeutics relevant for underserved populations who stand to benefit the most.

Registration: ISRCTN: [ISRCTN94098600](#) and ClinicalTrials.gov: [NCT0582059](#)

* * * *

Think Tanks

Brookings [to 07 Oct 2023]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 07 Oct 2023]

<https://www.cgdev.org/>

All Research [Selected]

WORKING PAPERS

[Identifying Macroeconomic Resilience to External Shocks in Emerging and Developing Countries: Lessons from the Global Shocks of 2020-2022](#)

Liliana Rojas-Suarez

October 05, 2023

This paper uses a straightforward Resilience Indicator, constructed from a small set of economic and institutional variables, to show that by 2019, prior to the COVID-19 pandemic and subsequent global shocks, it was possible to identify emerging markets and developing countries that would encounter serious economic and financial problems if an external shock were to materialize. The list of developing countries identified as less resilient in 2019 using this simple methodology closely aligns with the World Bank's 2022 compilation of countries in distress or at high risk of external debt distress. Furthermore, the emerging market economies that this indicator identified as the least resilient in 2019 were countries that had either defaulted or were teetering on the edge of default by 2022. Identifying countries that are most vulnerable to large external shocks can assist policymakers and the international community in directing their efforts towards crisis prevention, thereby avoiding the detrimental consequences of financial crises on development.

Chatham House [to 07 Oct 2023]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 07 Oct 2023]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

United States

[Preparing for the Next Pandemic Will Require Better Global Governance, Argues New CFR Report](#)

News Releases October 5, 2023

CSIS [to 07 Oct 2023]

<https://www.csis.org/>

Selected Reports, Events

No new digest content identified.

Kaiser Family Foundation [to 07 Oct 2023]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 07 Oct 2023]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 07 Oct 2023]

<https://odi.org/en/publications/>

Publications [Selected]

[Sex, health and rights in displacement and humanitarian response: crises upon crises in Lebanon and beyond](#)

05 October 2023

Case/country studies

Lebanon hosts the highest number of refugees per capita of any country in the world. Key amongst their pressing needs is services for sexual and reproductive health and rights (SRHR), which are often more acute at times of (and following) crisis when fertility rates tend to rise and gender-based violence increases.

SRHR is often seen as lower priority than other areas of humanitarian response, and existing SRHR programming typically focuses on maternal health and interventions related to gender-based violence for heterosexual, cisgender women of reproductive age. In so doing, it fails to address the breadth of SRHR needs and does little to recognise the differing experiences and needs of marginalised groups.

Using Lebanon as a case study, this project sets out to provide evidence of unmet needs for SRHR services in protracted crisis settings and their impacts, addressing persistent misconceptions about the criticality and need for such services...

Pew Research Center [to 07 Oct 2023]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 07 Oct 2023]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Journal Article

[US State Laws Relevant to Incentives for Health Behavior: A Qualitative Analysis](#)

The research team conducted a systematic NexisUni legal database review of state statutes and regulations effective during 2022 to identify laws relevant to contingency management.

Oct 5, 2023

Barbara Andraka-Christou, Michelle Williams, Scott Buksbaum, Josie Karkkainen, Bradley D. Stein, Sydney R. Batchelder, Kelly Peck, Sarah H. Heil, Richard A Rawson, Stacey C. Sigmon

Urban Institute [to 07 Oct 2023]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 07 Oct 2023]

<https://agenda.weforum.org/news/>

Media

No new digest content identified.

*

*

*

*

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *